phases list | enrollmentCount int64 | allocation string | interventionModel string | primaryPurpose class label | masking class label | healthyVolunteers bool | sex class label | oversightHasDmc bool | briefSummary string | detailedDescription string | conditions string | conditionsKeywords string | protocolPdfText string | numArms int64 | armDescriptions string | armGroupTypes list | numInterventions int64 | interventionTypes list | interventionDescriptions string | interventionNames string | numLocations int64 | locationDetails string | target int64 | nctid string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
[
3
] | 29 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | Primary Objective:
To evaluate efficacy and safety of ITF2357 in the treatment of patients with JAK2V617F positive myeloproliferative diseases \[Polycythemia Vera (PV), Essential Thrombocytosis (ET), Myelofibrosis (MF)\]. Efficacy was evaluated by ad hoc haematological and clinical criteria for PV and ET, and by inter... | This is a non-randomized, open-label, Phase IIA pilot study testing efficacy and safety of ITF2357 in a population of patients with JAK2V617F positive myeloproliferative diseases. All recruited patients received an initial dose of 50 mg b.i.d. of ITF2357 that was subsequently escalated to 50 mg t.i.d. in case of lack o... | Myeloproliferative Diseases | polycythemia vera (PV) essential thrombocythemia (ET) myelofibrosis (MF) | null | 1 | arm 1: Initial dose of 50 mg b.i.d. that was subsequently escalated to 50 mg t.i.d in case of lack of significant toxicity. | [
0
] | 1 | [
0
] | intervention 1: 50 mg b.i.d. PO every day. More precisely, ITF2357 was supplied as 50 mg hard gelatine capsules for oral administration. | intervention 1: ITF2357 | 2 | Bergamo | N/A | Italy | 9.66721 | 45.69601
Pavia | N/A | Italy | 9.15917 | 45.19205 | 0 | NCT00606307 |
[
5
] | 13 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | We are trying to learn if small changes in the amount of a valproate in the blood (given through an IV) will change the way the brain reacts to flashing lights. | Photosensitive epilepsy is a form of epilepsy that is considered to have a genetic basis in most instances. It is a reflex type of epilepsy. Patients with this condition exhibit epileptic activity patterns (called photoparoxysmal response-PPR) on their EEG during intermittent photic stimulation with certain flash frequ... | Photosensitive Epilepsy | epilepsy photosensitive valproic acid | null | 1 | arm 1: all patients will have placebo on day 1 and VPA infusion on day 2 | [
0
] | 2 | [
0,
0
] | intervention 1: The investigators will utilize intravenous sodium valproate at visit 3. Dosage will be individualized to each patient's body weight, age, and hepatic-enzyme-inducing status. Intravenous VPA dose predictions will be based upon population VPA pharmacokinetic parameters (Dutta 2003). intervention 2: Each p... | intervention 1: Valproic Acid intervention 2: Placebo | 2 | Chesterfield | Missouri | United States | -90.57707 | 38.66311
Nashville | Tennessee | United States | -86.78444 | 36.16589 | 0 | NCT00609245 |
[
3
] | 17 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | null | Non-Hodgin's lymphoma is curable in 76% of patients. In nonlymphoblastic lymphmas, cancer may return on average 3 months from beginning treatment and for lymphoblastic lymphomas, 6 months. To aggressively treat this cancer this study uses effective drugs in three parts:
* Induction ends on day 19
* Consolidation ends ... | null | Non-Hodgkin's Lymphoma | null | 1 | arm 1: None | [
0
] | 1 | [
0
] | intervention 1: LSA4 intervention includes three phases: induction, consolidation and maintenance | intervention 1: LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU | 1 | New York | New York | United States | -74.00597 | 40.71427 | 0 | NCT00610883 | |
[
3
] | 48 | NON_RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 1FEMALE | true | RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving letrozole together with erlotinib may k... | OBJECTIVES:
Primary
* To determine the rate of clinical benefit (complete response \[CR\], partial response \[PR\], and stable disease \[SD\] in patients with hormone-dependent locally recurrent or metastatic breast cancer treated with letrozole in combination with erlotinib hydrochloride.
Secondary
* To determine ... | Breast Cancer | recurrent breast cancer stage IV breast cancer | null | 2 | arm 1: None arm 2: None | [
0,
0
] | 5 | [
0,
0,
6,
10,
10
] | intervention 1: OSI-774 150 mg/day intervention 2: Letrozole 2.5 mg/day intervention 3: To determine HER2 gene amplification or excess copies of the HER2 gene intervention 4: to measure the epidermal growth factor receptors (EGFR) intervention 5: To determine if specific biomarkers exhibit a longer time to tumor progre... | intervention 1: erlotinib hydrochloride intervention 2: letrozole intervention 3: fluorescence in situ hybridization intervention 4: immunohistochemistry staining method intervention 5: laboratory biomarker analysis | 9 | Macon | Georgia | United States | -83.6324 | 32.84069
Hopkinsville | Kentucky | United States | -87.49117 | 36.86561
Paducah | Kentucky | United States | -88.60005 | 37.08339
Chattanooga | Tennessee | United States | -85.30968 | 35.04563
Germantown | Tennessee | United States | -89.81009 | 35.08676
Jackson | Tennessee ... | 0 | NCT00611715 |
[
3
] | 257 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | false | Randomized, multi-center, double-blind, placebo-controlled 12-week study to assess the safety and efficacy of 3 doses of an oral formulation of Doxycycline oral tablets using the Investigator's Global Assessment (IGA) score and the absolute change from baseline in inflammatory lesion count in patients with moderate to ... | null | Acne Vulgaris | null | 4 | arm 1: Doxycycline dosed at 40 mg/day to subjects of appropriate weights arm 2: Doxycycline dosed at 80 mg/day to subjects of appropriate weights arm 3: Doxycycline dosed at 160 mg/day to subjects of appropriate weights arm 4: None | [
0,
0,
0,
2
] | 4 | [
0,
0,
0,
0
] | intervention 1: doxycycline 40 mg/day, oral, 12 weeks intervention 2: doxycycline 80 mg/day, 12 weeks intervention 3: doxycycline 160 mg/day, 12 weeks intervention 4: Placebo, 12 weeks | intervention 1: Doxycycline 0.6 mg/kg/day intervention 2: Doxycycline 1.2 mg/kg/day intervention 3: Doxycycline 2.4 mg/kg/day intervention 4: Placebo | 23 | Encino | California | United States | -118.50119 | 34.15917
Fremont | California | United States | -121.98857 | 37.54827
Los Angeles | California | United States | -118.24368 | 34.05223
Sacramento | California | United States | -121.4944 | 38.58157
Denver | Colorado | United States | -104.9847 | 39.73915
Miami | Florid... | 0 | NCT00612573 | |
[
4
] | 169 | RANDOMIZED | CROSSOVER | 0TREATMENT | 2DOUBLE | false | 0ALL | false | The study compared the 24-hour spirometry profile of indacaterol with that of placebo and with tiotropium as an active control in patients with chronic obstructive pulmonary disease. | null | Chronic Obstructive Pulmonary Disease (COPD) | Chronic obstructive pulmonary disease, indacaterol, tiotropium, placebo controlled | null | 4 | arm 1: In period I, placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium inhalation device. In period II, tiotropium (18 μg) once daily delivered via inhalation device and matching placebo to indacaterol delivered once daily via single dose dry... | [
0,
0,
0,
0
] | 3 | [
0,
0,
0
] | intervention 1: Indacaterol 150 μg or 300 μg, delivered via SDDPI intervention 2: Tiotropium 18 μg once daily delivered via inhalation device intervention 3: Placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium manufacturer's proprietary inhala... | intervention 1: Indacaterol intervention 2: Tiotropium intervention 3: Placebo | 20 | Camperdown | N/A | Australia | 151.17642 | -33.88965
Gauting | N/A | Germany | 11.37703 | 48.06919
Großhansdorf | N/A | Germany | 10.28333 | 53.66667
Mainz | N/A | Germany | 8.2791 | 49.98419
Marburg | N/A | Germany | 8.77069 | 50.80904
Wiesbaden | N/A | Germany | 8.24932 | 50.08258
Almelo | N/A | Netherlands | 6.6625 ... | 0 | NCT00615459 |
[
3
] | 456 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | false | To determine the safety and efficacy of SEP-225441 (eszopiclone) in subjects with generalized anxiety disorder (GAD). | This is a multicenter, randomized, double blind, placebo controlled study of the safety and efficacy of SEP-225441 (eszopiclone) in male and female adult subjects with a diagnosis of generalized anxiety disorder (GAD). The study consists of a screening period of 7-10 days, 8 weeks of treatment, and a 7 day follow-up pe... | Generalized Anxiety Disorder | Anxiety | null | 3 | arm 1: SEP-225441 (eszopiclone) total daily dose of 1.5 mg arm 2: SEP-225441 (eszopiclone) total daily dose of 0.9 mg arm 3: Placebo total daily dose 0.9 mg | [
1,
1,
2
] | 3 | [
0,
0,
0
] | intervention 1: SEP-225441 (eszopiclone) total daily dose of 1.5 mg intervention 2: SEP-225441 (eszopiclone) total daily dose of 0.9 mg intervention 3: Placebo total daily dose 0.9 mg | intervention 1: eszopiclone intervention 2: eszopiclone intervention 3: Placebo | 57 | Birmingham | Alabama | United States | -86.80249 | 33.52066
Arcadia | California | United States | -118.03534 | 34.13973
Beverly Hills | California | United States | -118.40036 | 34.07362
Burbank | California | United States | -118.30897 | 34.18084
Glendale | California | United States | -118.25508 | 34.14251
Glendale ... | 0 | NCT00616655 |
[
3
] | 73 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | Phase 2 trial to evaluate the safety and potential efficacy of one concentration of deoxycholic acid injection, given in three dosing paradigms, compared to placebo for the reduction of submental fat (fat beneath the chin). | null | Moderate or Severe Submental Fullness | null | 6 | arm 1: Participants received deoxycholic acid administered in 0.2 mL injections, 0.7 cm apart, up to 9.6 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments. arm 2: Participants received placebo administered in 0.2 mL injections, 0.7 cm apart, up to 9.6 mL per treatment se... | [
0,
2,
0,
2,
0,
2
] | 2 | [
0,
0
] | intervention 1: Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL. intervention 2: None | intervention 1: Deoxycholic Acid Injection intervention 2: Placebo | 7 | Toorak | Victoria | Australia | 145.01438 | -37.84165
Sydney | N/A | Australia | 151.20732 | -33.86785
Niagara Falls | Ontario | Canada | -79.06627 | 43.10012
Oakville | Ontario | Canada | -79.68292 | 43.45011
Toronto | Ontario | Canada | -79.39864 | 43.70643
Toronto | Ontario | Canada | -79.39864 | 43.70643
Manchester... | 0 | NCT00618618 | |
[
4
] | 343 | NON_RANDOMIZED | SINGLE_GROUP | 2DIAGNOSTIC | 0NONE | false | 0ALL | false | This is a study involving the use of Magnetic Resonance Imaging (MRI) contrast agents called Gadavist. The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of Gadavist when used for taking images of the brain and spine. The results of the MRI will be compar... | Issues on safety will be addressed in Adverse Events section. | Central Nervous System Diseases | Central Nervous System Imaging Diagnostic Imaging | null | 1 | arm 1: Participants were administered a single dose of gadobutrol 0.1 mmol/kg body weight (bw) via i.v. (intravenous) bolus administration using a power injector via a peripheral vein (an antecubital vein was preferred). Gadobutrol was injected at a rate of 2 mL/second followed by a 20-mL 0.9% saline flush at the same ... | [
0
] | 1 | [
0
] | intervention 1: Gadobutrol single injection 0.1 mmol/kg BW via IV bolus administration at 2mL/sec. | intervention 1: Gadobutrol (Gadavist, Gadovist, BAY86-4875) | 37 | Phoenix | Arizona | United States | -112.07404 | 33.44838
Scottsdale | Arizona | United States | -111.89903 | 33.50921
Tucson | Arizona | United States | -110.92648 | 32.22174
Los Angeles | California | United States | -118.24368 | 34.05223
Los Angeles | California | United States | -118.24368 | 34.05223
San Diego | Ca... | 0 | NCT00623467 |
[
1
] | 12 | RANDOMIZED | CROSSOVER | 7BASIC_SCIENCE | 0NONE | false | 0ALL | false | Summary:
A picture is emerging of dendritic cells migrating through the blood to the airways following allergen inhalation in atopic asthmatics. Although the Koh and McCarthy articles present novel findings, both do not provide a comprehensive view of sputum DCs following allergen challenge. Therefore, the proposed st... | Subjects will be put through two study periods. Each study period will consist of four visits and will be separated by 2-4 weeks. On the first visit, subjects will undergo screening procedures, including complete history and physical examination. In addition, methacholine inhalation challenge and skin-prick testing wil... | Asthma | asthma atopy allergen challenge sputum myeloid and plasmacytoid dendritic cells | null | 2 | arm 1: Inhalation challenge preformed with diluent. arm 2: Inhalation challenge preformed with allergen. | [
2,
1
] | 1 | [
0
] | intervention 1: None | intervention 1: Aeroallergen | 1 | Hamilton | Ontario | Canada | -79.84963 | 43.25011 | 0 | NCT00625989 |
[
4
] | 602 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | false | This study is to evaluate the efficacy of esomeprazole 20 mg once daily and 40 mg once daily for 8 weeks on healing of Reflux Esophagitis in patients with reflux esophagitis in comparison with omeprazole 20 mg once daily by assessment of presence/absence of Reflux Esophagitis at Week 8 according to the Los Angeles clas... | null | Reflux Esophagitis | Reflux Esophagitis | null | 3 | arm 1: Esomeprazole 20mg arm 2: Esomeprazole 40mg arm 3: Omeprazole 20mg | [
0,
0,
1
] | 3 | [
0,
0,
0
] | intervention 1: 20mg once daily intervention 2: 40 mg once daily intervention 3: 20mg once daily | intervention 1: Esomeprazole intervention 2: Esomeprazole intervention 3: Omeprazole | 41 | Akita | Akita | Japan | 140.11667 | 39.71667
Kashiwa | Chiba | Japan | 139.97732 | 35.86224
Kisarazu | Chiba | Japan | 139.93254 | 35.38329
Kōriyama | Fukishima | Japan | 140.38333 | 37.4
Nihonmatsu | Fukishima | Japan | 139.26427 | 37.96201
Nishishirakawa | Fukishima | Japan | N/A | N/A
Fukuoka | Fukuoka | Japan | 130... | 0 | NCT00633932 |
[
3
] | 261 | RANDOMIZED | PARALLEL | 0TREATMENT | 3TRIPLE | false | 0ALL | false | The purpose of this study is to learn which doses of PS433540 should be given to patients with high blood pressure to lower their blood pressure. This study will also examine how safe PS433540 is when taken by patients with high blood pressure. Approximately 720 patients will be evaluated so that about 375 patients wil... | null | Hypertension | Hypertension High Blood Pressure | null | 5 | arm 1: Irbesartan 300 mg once daily arm 2: Blinded Placebo Treatment arm 3: PS433540 200mg once daily arm 4: PS433540 400mg once daily arm 5: PS433540 800mg once daily | [
1,
2,
0,
0,
0
] | 5 | [
0,
0,
0,
0,
0
] | intervention 1: 300 mg (2 x 150 mg capsules) once daily for 12 weeks intervention 2: placebo capsules once daily for 12 weeks intervention 3: 200 mg (2 x 100 mg capsules) once daily for 12 weeks intervention 4: 400 mg (4 x 100 mg capsules) once daily for 12 weeks intervention 5: 800 mg (8 x 100 mg capsules) once daily ... | intervention 1: irbesartan intervention 2: placebo intervention 3: PS433540 intervention 4: PS433540 intervention 5: PS433540 | 40 | Pell City | Alabama | United States | -86.28609 | 33.58621
Tempe | Arizona | United States | -111.90931 | 33.41477
Tucson | Arizona | United States | -110.92648 | 32.22174
Anaheim | California | United States | -117.9145 | 33.83529
Buena Park | California | United States | -117.99812 | 33.86751
Lincoln | California | U... | 0 | NCT00635232 |
[
5
] | 1,570 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | The purpose of this study is to provide information in a broad, "real world" population of chronic pain patients assessing both pain control with AVINZA as well as the potential risk for misuse and abuse. | Pain affects more Americans than diabetes, heart disease and cancer combined and although it is one of the earliest known ailments, pain is still without a universal cure. It is estimated that only about 25% of patients with chronic pain receive adequate analgesia.
Long-term treatment of chronic pain with opioids is r... | Pain | pain opioid abuse moderate-severe pain requiring continuous, around-the-clock opioid therapy for an extended period of time | null | 1 | arm 1: None | [
0
] | 1 | [
0
] | intervention 1: 30 mg, 60 mg, 90 mg, 120 mg morphine will be prescribed by the Investigator in accordance with the AVINZA prescribing information. | intervention 1: morphine sulfate extended release capsules | 384 | Adamsville | Alabama | United States | -86.95611 | 33.60094
Phoenix | Arizona | United States | -112.07404 | 33.44838
Scottsdale | Arizona | United States | -111.89903 | 33.50921
Sun City | Arizona | United States | -112.27182 | 33.59754
Sun Lakes | Arizona | United States | -111.87542 | 33.21116
Tucson | Arizona | Uni... | 0 | NCT00640042 |
[
1
] | 20 | RANDOMIZED | CROSSOVER | 0TREATMENT | 4QUADRUPLE | false | 0ALL | false | Pregabalin is approved for the treatment of nerve pain as well as an additional therapy in the treatment of seizures. In December 2004, Pfizer gained Food and Drug Administration (FDA) approval for use of pregabalin in nerve pain associated with diabetes and shingles; making it the first FDA-approved treatment for both... | Overview We propose a single site, double-blind, placebo-controlled, cross-over design. Drug will be administered in 75mg capsules with a target dose of 300 mg/day. Pregabalin will be titrated upward as described in the "Summary of Schedule" table with flexibility. During weeks 3-5 and 12-14, the investigator will have... | Essential Tremor | Essential tremor Activities of Daily Living (ADL's) | null | 2 | arm 1: Pregabalin (Lyrica) 75 mg bid to a maximum dose of 300 mg bid arm 2: Placebo to 4 capsules bid | [
1,
2
] | 2 | [
0,
0
] | intervention 1: 75 mg bid to 300 mg bid based on per subject tolerability intervention 2: up to 4 capsules bid as tolerated | intervention 1: pregabalin (Lyrica) intervention 2: placebo | 1 | Houston | Texas | United States | -95.36327 | 29.76328 | 0 | NCT00646451 |
[
0
] | 26 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | null | The purpose of this study is to determine if we can prevent Epstein Barr Virus lymphomas by the monthly administration of an (antibody) protein against B lymphocytes called Rituximab. Although this medicine has been approved by the Food and Drug Administration to treat patients with other types of lymphomas, and has be... | null | Hodgkin's Disease Leukemia Myelodysplastic Syndrome Non-Hodgkin's Lymphoma | RITUXIMAB Lymphoma | null | 1 | arm 1: Patients following a T cell depleted HLA-mis-matched related or unrelated hematopoietic stem cell transplant (HSCT) will be treated with monthly Rituximab. | [
0
] | 1 | [
0
] | intervention 1: Rituximab 375 mg/m\^2 starting approximately 1 month post transplant (no later than day 45), and continuing monthly until the CD4 cell count is \> 200 cells/ul or a maximum of 6 doses have been given. | intervention 1: Rituximab | 1 | New York | New York | United States | -74.00597 | 40.71427 | 0 | NCT00648037 |
[
4
] | 29 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | This pilot trial in Finland is designed to evaluate in a randomized fashion change of agitation in acute schizophrenic patients (Schizophrenia or Schizoaffective psychosis or Schizophreniformic psychosis)Diagnostic and Statistical Manual (DSM - IV) with the first visits on days 1, 2, 4 or 5 and 7 ± 1. | null | Schizophrenic Disorders | Schizophrenia Schizoaffective psychosis Schizophreniformic psychosis Pilot study Quetiapine Prolong Risperidone | null | 2 | arm 1: Oral arm 2: Oral | [
0,
1
] | 2 | [
0,
0
] | intervention 1: Oral administration intervention 2: Oral administration | intervention 1: Quetiapine intervention 2: Risperidone | 4 | Harjavalta | N/A | Finland | 22.13333 | 61.31667
Helsinki | N/A | Finland | 24.93545 | 60.16952
Pitkäniemi | N/A | Finland | 23.57654 | 61.48226
Turku | N/A | Finland | 22.26869 | 60.45148 | 0 | NCT00660595 |
[
3
] | 29 | RANDOMIZED | CROSSOVER | 0TREATMENT | 0NONE | false | 0ALL | null | 28 subjects to be enrolled for a screening period, 3 dosing visits \& a follow-up visit. Visits 2 and 3 dosing of TI Inhalation Powder, cross over between two 15 U cartridges and one 30 U cartridge. Visit 4 dosing will be a sc injection of 10 IU of RAA (rapid-acting insulin analogue). | 28 eligible subjects were planned to be enrolled to determine bioequivalence and safety parameters of two 15 U TI Inhalation Powder cartridges versus one 30 U TI Inhalation Powder cartridge, according to a randomized, 2-way crossover design. Additionally, bioavailability of one 30 U TI Inhalation Powder cartridge to a ... | Diabetes Mellitus: Type 1 | Diabetic adult male, diabetic adult female | null | 3 | arm 1: Technosphere® Insulin Inhalation Powder, two 15 U cartridges arm 2: Technosphere® Insulin Inhalation Powder, one 30 U cartridge arm 3: Rapid Acting Analogue subjects received 10 IU sc Insulin Lispro | [
0,
0,
0
] | 3 | [
0,
0,
0
] | intervention 1: TI Inhalation Powder, two 15 U cartridges intervention 2: TI Inhalation Powder, one 30 U cartridge intervention 3: RAA Population: All subjects received a single 10 IU sc injection of insulin lispro. | intervention 1: Technosphere® Insulin Inhalation Powder intervention 2: Technosphere Insulin® Inhalation Powder intervention 3: RAA Population | 2 | Chula Vista | California | United States | -117.0842 | 32.64005
San Antonio | Texas | United States | -98.49363 | 29.42412 | 0 | NCT00662857 |
[
2
] | 20 | NON_RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | Phase 1 study in HVC (Hepatitis C Virus) infected subjects to determine pharmacokinetics, safety and efficacy in subjects with no or inadequate response to prior treatment. | null | Hepatitis, Chronic Hepatitis C Virus | null | 2 | arm 1: None arm 2: Dose study drug in subjects who have previously failed to respond to interferon based therapies | [
0,
0
] | 2 | [
0,
0
] | intervention 1: Study drug will be administered 700mg BID in the fed state for three days. intervention 2: Study drug will be given 450mg BID for a duration of 10 days. | intervention 1: Small Molecule Agent (PF-868554) intervention 2: Small Molecule Agent (PF-868554) | 1 | Gainesville | Florida | United States | -82.32483 | 29.65163 | 0 | NCT00671671 | |
[
3
] | 20 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | In this multicenter study, patients with dark skin and acne vulgaris will be included. The patients will receive treatment with MAL PDT and placebo PDT. | The treatment period started within 2 weeks of the study screen. Patients received two treatments (MAL PDT and vehicle PDT) to each of the treatment areas, 2 weeks apart, and were followed-up 4 weeks after last treatment. The total duration of the study was 6-8 weeks.
Methyl aminolevulinate 80 mg/g cream (MAL cream 8%... | Acne Vulgaris | null | 2 | arm 1: PDT using MAL crem arm 2: PDT using Placebo cream | [
0,
2
] | 1 | [
0
] | intervention 1: Cream application followed by illumination with red light | intervention 1: Methyl aminolevulinate (MAL) PDT | 2 | Naperville | Illinois | United States | -88.14729 | 41.78586
Albuquerque | New Mexico | United States | -106.65114 | 35.08449 | 0 | NCT00673933 | |
[
5
] | 53 | RANDOMIZED | PARALLEL | 9OTHER | 4QUADRUPLE | false | 0ALL | false | The main purposes of this study are to find out if the study drug losartan (Cozaar) or placebo ("sugar pill") has an effect on insulin sensitivity (how your body responds to insulin) and to measure the effect of the study drug losartan or placebo on how the arteries in your arm dilate (enlarge to carry more blood).
We... | null | Obesity Hypertension Hyperglycemia | Impaired Fasting Glucose FPG >100-<126 mg/dL | null | 2 | arm 1: Losartan 100 mg 1 tab po QD arm 2: Placebo 1 tab po QD | [
1,
2
] | 2 | [
0,
0
] | intervention 1: losartan 100 mg tablets 1 tab po QD intervention 2: Placebo 1 po QD | intervention 1: losartan intervention 2: Placebo control | 9 | Little Rock | Arkansas | United States | -92.28959 | 34.74648
San Diego | California | United States | -117.16472 | 32.71571
Miami | Florida | United States | -80.19366 | 25.77427
Indianapolis | Indiana | United States | -86.15804 | 39.76838
Boston | Massachusetts | United States | -71.05977 | 42.35843
New York | New Y... | 0 | NCT00675987 |
[
3
] | 33 | NA | SINGLE_GROUP | 7BASIC_SCIENCE | 0NONE | false | 2MALE | true | The purpose of the study is to see if a green tea extract can beneficially alter several markers of cancer risk and progression. | To evaluate the short-term effects of a daily dose of Polyphenon E administered during the interval between prostate biopsy and radical prostatectomy in men with recently diagnosed prostate cancer. Endpoints will be changes in serum and tissue biomarkers related to progression of cancer.
The effect of Polyphenon E on ... | Prostate Cancer | EGCG polyphenols biomarkers prostate specific antigen | null | 1 | arm 1: Single arm for a phase II study | [
0
] | 1 | [
0
] | intervention 1: 4 capsules daily with a meal for the duration of the study | intervention 1: Polyphenon E (EGCG) | 1 | Shreveport | Louisiana | United States | -93.75018 | 32.52515 | 0 | NCT00676780 |
[
5
] | 45 | NON_RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | true | 1FEMALE | false | The purpose of the study proposed is to investigate the role of neurosteroids and GABA in the pathophysiology and treatment of premenstrual dysphoric disorder (PMDD) by 1) measuring cortical gama-aminobutyric acid levels (GABA levels) using nuclear magnetic resonance spectroscopy (MRS) during the follicular and mid-lut... | null | Premenstrual Dysphoric Disorder Premenstrual Syndrome | hormones menses PMS PMDD | null | 2 | arm 1: PMDD group received fluoxetine 20 mg daily by mouth for 2-3 months arm 2: None | [
0,
4
] | 1 | [
0
] | intervention 1: Fluoxetine 20 mg daily by mouth for 2-3 months. | intervention 1: fluoxetine | 1 | New Haven | Connecticut | United States | -72.92816 | 41.30815 | 0 | NCT00678574 |
[
0
] | 21 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | true | 1FEMALE | true | Increased insulin levels leads to increased secretion of D-chiro inositol(DCI) from the kidneys in women with PCOS, but not in normal women. This leads to a reduction in circulating DCI and insulin stimulated release of DCI-IPG.To determine if decreasing circulating insulin directly by inhibition of islet insulin relea... | null | PCOS | null | 2 | arm 1: PCOS subjects given diazoxide arm 2: Normal subjects given diazoxide | [
0,
1
] | 1 | [
0
] | intervention 1: 100mg orally three times per day for 10 days | intervention 1: diazoxide | 1 | Richmond | Virginia | United States | -77.46026 | 37.55376 | 0 | NCT00683774 | |
[
2
] | 19 | RANDOMIZED | PARALLEL | 9OTHER | 1SINGLE | true | 0ALL | false | The radial artery, which is located on the outer side of the forearm, can be used in interventional procedures, such as cardiac catheterization, to provide access to the arterial blood supply. In order to facilitate successful catheterization of the artery, a dilated artery and one free of arterial spasm is desirable. ... | During the first study visit, as a dose-optimizing study, each subject will be randomly assigned to one of two Dose-Test arms to receive either 15mg or 30mg of nitroglycerin on one wrist and placebo on the other. Radial artery diameter will be measured with ultrasound at regular intervals up to two hours. On the second... | Healthy | To determine if topical nitroglycerin acts to vasodilate the radial artery by a direct local action, or by systemic vasodilation To determine if topical nitroglycerin dilates the radial artery in the presence of local anesthetic agents used in cardiac catheterization | null | 4 | arm 1: Nitroglycerin 15mg (NTG) applied topically to one wrist and placebo to the other wrist at Visit 1 arm 2: Nitroglycerin 30mg applied topically to one wrist and placebo to the other wrist at Visit 1 arm 3: Lidocaine 20mg + Nitroglycerin 30mg applied topically to one wrist, Lidocaine 20mg + placebo applied to the o... | [
0,
0,
0,
0
] | 5 | [
0,
0,
0,
0,
0
] | intervention 1: 15mg Nitroglycerin applied topically to one wrist intervention 2: 30mg Nitroglycerin applied topically to one wrist intervention 3: 20mg Lidocaine applied topically to one wrist in combination with nitroglycerin or placebo intervention 4: 40mg Lidocaine applied topically to one wrist in combination with... | intervention 1: Nitroglycerin 15mg intervention 2: Nitroglycerin 30mg intervention 3: Lidocaine 20mg intervention 4: Lidocaine 40mg intervention 5: Placebo | 1 | San Francisco | California | United States | -122.41942 | 37.77493 | 0 | NCT00686231 |
[
4
] | 336 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | false | The purpose of the study is to demonstrate the safety and efficacy of U0267 in subjects with plaque-type psoriasis. | null | Psoriasis | Plaque-type Psoriasis Psoriasis | null | 2 | arm 1: U0267 is a vitamin D3 analog (calcipotriene) foam. It is applied twice a day for 8 weeks to psoriasis lesions on the body. arm 2: Vehicle foam is the same as the U0267 foam except that it does not have the active ingredient. It is applied twice a day for 8 weeks to psoriasis lesions on the body. | [
0,
2
] | 2 | [
0,
0
] | intervention 1: All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp). intervention 2: All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding... | intervention 1: U0267 intervention 2: Vehicle | 13 | San Diego | California | United States | -117.16472 | 32.71571
Denver | Colorado | United States | -104.9847 | 39.73915
Miami | Florida | United States | -80.19366 | 25.77427
Miami | Florida | United States | -80.19366 | 25.77427
Louisville | Kentucky | United States | -85.75941 | 38.25424
Boston | Massachusetts | Unit... | 0 | NCT00688519 |
[
3
] | 118 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | false | The purpose of this study is to study efficacy and safety of AZD1981 in patients with Chronic Obstructive Pulmonary Disease | null | Moderate to Severe COPD | COPD | null | 2 | arm 1: AZD1981 Oral tablet, twice daily arm 2: Placebo Oral tablet, twice daily | [
0,
2
] | 2 | [
0,
0
] | intervention 1: Oral tablet, twice daily intervention 2: Placebo Oral tablet, twice daily | intervention 1: AZD1981 intervention 2: Placebo | 21 | Pleven | N/A | Bulgaria | 24.61667 | 43.41667
Rousse | N/A | Bulgaria | 25.9534 | 43.84872
Sofia | N/A | Bulgaria | 23.32415 | 42.69751
Varna | N/A | Bulgaria | 27.91667 | 43.21667
Arhus C | N/A | Denmark | N/A | N/A
Hellerup | N/A | Denmark | 12.57093 | 55.73204
Hvidovre | N/A | Denmark | 12.47708 | 55.64297
Værløse |... | 0 | NCT00690482 |
[
4
] | 17 | RANDOMIZED | CROSSOVER | 0TREATMENT | 2DOUBLE | false | 0ALL | true | This study will assess the effect of pancrelipase delayed release 12,000 unit capsules on fat and nitrogen absorption in subjects 7 - 11 with pancreatic exocrine insufficiency due to Cystic Fibrosis. | null | Cystic Fibrosis Pancreatic Exocrine Insufficiency | Cystic Fibrosis Pancreatic Exocrine Insufficiency | null | 2 | arm 1: None arm 2: None | [
0,
2
] | 2 | [
0,
0
] | intervention 1: 12,000 unit Capsules, dosed individually based on fat intake. intervention 2: Placebo | intervention 1: Pancrelipase Delayed Release intervention 2: Placebo Comparator | 10 | Iowa City | Iowa | United States | -91.53017 | 41.66113
Louisville | Kentucky | United States | -85.75941 | 38.25424
Boston | Massachusetts | United States | -71.05977 | 42.35843
Ann Arbor | Michigan | United States | -83.74088 | 42.27756
Minneapolis | Minnesota | United States | -93.26384 | 44.97997
Albuquerque | New ... | 0 | NCT00690820 |
[
3
] | 184 | NON_RANDOMIZED | SINGLE_GROUP | 2DIAGNOSTIC | 1SINGLE | true | 0ALL | false | Evaluate 18F-AV-45 positron emission tomography (PET) imaging for distinguishing healthy control subjects, from subjects with Alzheimer's disease (AD) or Mild cognitive impairment (MCI). | null | Alzheimer's Disease Mild Cognitive Impairment | null | 3 | arm 1: None arm 2: MCI (mild cognitive impairment) arm 3: None | [
0,
0,
0
] | 1 | [
0
] | intervention 1: IV injection, 370MBq (10mCi), single dose | intervention 1: florbetapir F 18 | 15 | Phoenix | Arizona | United States | -112.07404 | 33.44838
Scottsdale | Arizona | United States | -111.89903 | 33.50921
Sun City | Arizona | United States | -112.27182 | 33.59754
Tucson | Arizona | United States | -110.92648 | 32.22174
Costa Mesa | California | United States | -117.91867 | 33.64113
New Haven | Connectic... | 0 | NCT00702143 | |
[
3
] | 142 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | false | The primary objective of this study are to evaluate the synergistic effect of a combination product, consisting of drug BCI-024 (buspirone) and drug BCI-049 (melatonin), in reducing symptoms of depression in patients with Major Depressive Disorder.
The safety and tolerability of the combination product will also be ev... | Approximately 120 adult outpatients meeting the study's inclusion and exclusion criteria will be randomized in the study. | Major Depressive Disorder | depression | null | 3 | arm 1: BCI-024: over-encapsulated Buspirone tablet 15 mg at bedtime(QD) and BCI-049: over-encapsulated Melatonin tablet 3 mg QD arm 2: BCI-024: over-encapsulated Buspirone 15 mg QD arm 3: Placebo: 1 capsule QD | [
0,
1,
2
] | 3 | [
0,
0,
0
] | intervention 1: BCI-024: over-encapsulated Buspirone tablet 15 mg QD and Drug BCI-049: over-encapsulated Melatonin tablet 3 mg QD taken in combination for 6 weeks intervention 2: Drug BCI-024 (Buspirone) taken once a day at bedtime for 6 weeks. intervention 3: Placebo comparator once a day at bedtime for 6 weeks. | intervention 1: BCI-024: over-encapsulated Buspirone tablet 15 mg QD and BCI-049: over-encapsulated Melatonin tablet 3 mg QD intervention 2: BCI-024 (Buspirone) intervention 3: Matching placebo | 9 | Garden Grove | California | United States | -117.94145 | 33.77391
San Diego | California | United States | -117.16472 | 32.71571
Altanta | Georgia | United States | N/A | N/A
Rockville | Maryland | United States | -77.15276 | 39.084
Beachwood | Ohio | United States | -81.50873 | 41.4645
Philadelphia | Pennsylvania | Un... | 0 | NCT00705003 |
[
3
] | 87 | null | PARALLEL | 0TREATMENT | null | false | 2MALE | null | The primary objective of this trial is to estimate and compare the 12-week progression-free rate of BIBF 1120, BIBW 2992 or sequential administration of BIBF 1120 and BIBW 2992 in patients with HRPC as determined by radiographic, bone and PSA criteria. | null | Prostatic Neoplasms | null | 0 | null | null | 3 | [
0,
0,
0
] | intervention 1: None intervention 2: None intervention 3: None | intervention 1: BIBF 1120 intervention 2: BIBW 2992 intervention 3: Sequential BIBF 1120 + BIBW 2992 | 9 | Belfast | N/A | United Kingdom | -5.92541 | 54.59682
Bournemouth | N/A | United Kingdom | -1.8795 | 50.72048
Brighton | N/A | United Kingdom | -0.13947 | 50.82838
Cheltenham | N/A | United Kingdom | -2.07972 | 51.90006
Glasgow | N/A | United Kingdom | -4.25763 | 55.86515
Newcastle upon Tyne | N/A | United Kingdom | -1.... | 0 | NCT00706628 | |
[
5
] | 16 | RANDOMIZED | CROSSOVER | 2DIAGNOSTIC | 1SINGLE | true | 0ALL | false | The purpose of this study is to use functional magnetic resonance imaging (fMRI) in healthy controls to examine the acute effects of certain anxiolytic medications on brain function. In this case, the medication pregabalin will be used. The investigators hypothesize that pregabalin (at doses of 50 mg and 200 mg, versus... | Increased amygdala and insula activity have been implicated in neurobiological models of anxiety. Using fMRI, the anxiolytic medication, lorazepam, has previously been found to decrease activation in these areas during the processing of emotional stimuli. This study aims to replicate those results but by using a differ... | Anxiety Disorders | anxiety functional magnetic resonance imaging fMRI pregabalin Lyrica | null | 3 | arm 1: Pregabalin oral tablets (50 mg) arm 2: Pregabalin oral tablets (200 mg) arm 3: Placebo | [
1,
1,
2
] | 3 | [
0,
0,
0
] | intervention 1: One dose of oral pregabalin (50 mg) to be administered one hour prior to fMRI scan intervention 2: One dose of oral pregabalin (200 mg) to be administered one hour prior to fMRI scan intervention 3: One dose of matched oral placebo to be administered one hour prior to fMRI scan | intervention 1: Pregabalin 50mg intervention 2: Pregabalin 200 MG intervention 3: placebo | 1 | La Jolla | California | United States | -117.2742 | 32.84727 | 0 | NCT00706836 |
[
0
] | 40 | NON_RANDOMIZED | PARALLEL | null | 0NONE | true | 1FEMALE | false | There are over 60 million women of reproductive age in the U.S. and a majority of these women qualify as overweight or obese. Evidence suggests that there is an association between increased body weight and decreased contraceptive efficacy. Studies with the combined hormonal contraceptive patch (Evra®) and the subderma... | null | Pharmacokinetics | contraceptive ring obesity pharmacokinetics pharmacodynamics Pharmacokinetics of the contraceptive ring in obese women. | null | 2 | arm 1: Obese subjects (BMI 30-39.9)received two contraceptive hormonal rings. During the second cycle of ring use, subjects returned to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use. arm 2: Normal weight subjects (BMI 19-24.9) received ... | [
0,
1
] | 2 | [
0,
0
] | intervention 1: Obese subjects (BMI 30-39.9) will receive two contraceptive hormonal rings. During the second cycle of ring use, subjects will return to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use. intervention 2: Normal weight subjec... | intervention 1: NuvaRing intervention 2: NuvaRing | 1 | New York | New York | United States | -74.00597 | 40.71427 | 0 | NCT00710606 |
[
5
] | 7 | RANDOMIZED | CROSSOVER | 7BASIC_SCIENCE | 2DOUBLE | false | 0ALL | false | The investigators propose a 3-treatment, placebo-controlled, double-dummy, double-blinded, randomized, crossover study in which single doses of placebo, will be compared to Fluticasone propionate (Flovent Diskus) 250 mcg and budesonide 400 mcg administered after allergen challenge, at cessation of the early allergic re... | The aim of this pilot study is to evaluate whether fluticasone propionate affects the late allergic reaction after a single dose post-allergen challenge administered following cessation of the early allergic reaction.
Six subjects with mild asthma will be asked to volunteer for the study.The diagnosis of asthma will b... | Mild Intermittent Asthma | late allergic response fluticasone propionate | null | 3 | arm 1: Fluticasone propionate (Flovent Diskus) 250 mcg arm 2: budesonide 400mcg arm 3: placebo | [
1,
1,
2
] | 3 | [
0,
0,
10
] | intervention 1: Flovent Diskus 250 mcg intervention 2: budesonide 400 mcg intervention 3: Placebo | intervention 1: Fluticasone propionate (Flovent Diskus) 250 mcg intervention 2: budesonide 400 mcg intervention 3: Placebo | 1 | Hamilton | Ontario | Canada | -79.84963 | 43.25011 | 0 | NCT00716963 |
[
4
] | 259 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 1FEMALE | false | The primary purpose of this study is to assess that ganirelix is safe and well-tolerated in Chinese women and that a controlled ovarian stimulation (COS) protocol combining recombinant follicle stimulating hormone (recFSH) with ganirelix is efficient in Chinese women undergoing COS for in vitro fertilization (IVF) or i... | null | Controlled Ovarian Stimulation | Reproductive techniques assisted | null | 2 | arm 1: ganirelix arm 2: triptorelin | [
0,
1
] | 2 | [
0,
0
] | intervention 1: On day 6 of recFSH treatment, Org 37462 treatment will start by daily SC administration (0.25 mg) up to and including the day of hCG administration. intervention 2: a daily dose of 0.05 mg SC is to be injected. Triptorelin treatment will start in the luteal phase at day 21-24 of the menstrual cycle. Tre... | intervention 1: ganirelix intervention 2: triptorelin | 0 | null | 0 | NCT00725491 |
[
5
] | 261 | NON_RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | This is a post marketing study to confirm the appropriate dose of loratadine in children by obtaining drug concentration data at multiple time points per child and adult patient, after the patient receives repeated administrations of the approved dose of loratadine. | null | Perennial Allergic Rhinitis | null | 3 | arm 1: Pediatrics 3 to 6 years arm 2: Pediatrics 7 to 15 years arm 3: Adults 16 to 64 years | [
0,
0,
0
] | 3 | [
0,
0,
0
] | intervention 1: Loratadine (SCH 29851) dry syrup 1% 5 mg/day for 4 weeks intervention 2: loratadine 10 mg tablet once daily for 4 weeks intervention 3: loratadine 10 mg tablet once daily for 4 weeks | intervention 1: loratadine intervention 2: loratadine intervention 3: loratadine | 0 | null | 0 | NCT00730912 | |
[
3
] | 37 | RANDOMIZED | CROSSOVER | 0TREATMENT | 4QUADRUPLE | false | 0ALL | false | The purpose of this study is to investigate the pharmacodynamics of single doses of AZD3199 in asthmatic patients. | null | Asthma Airway Obstruction | Asthma airway obstruction beta2-agonist efficacy inhalation | null | 6 | arm 1: AZD3199 120 microgram arm 2: AZD3199 480 microgram arm 3: AZD3199 1920 microgram arm 4: Placebo arm 5: Formoterol 9 microgram arm 6: Formoterol 36 microgram | [
0,
0,
0,
2,
1,
1
] | 3 | [
0,
0,
0
] | intervention 1: Dry powder for inhalation, single dose intervention 2: Dry powder for inhalation, single dose intervention 3: Dry powder for inhalation, single dose | intervention 1: AZD3199 intervention 2: Formoterol intervention 3: Placebo | 4 | Hvidovre | N/A | Denmark | 12.47708 | 55.64297
Gothenburg | N/A | Sweden | 11.96679 | 57.70716
Luleå | N/A | Sweden | 22.15465 | 65.58415
Lund | N/A | Sweden | 13.19321 | 55.70584 | 0 | NCT00736489 |
[
2
] | 68 | RANDOMIZED | CROSSOVER | 0TREATMENT | 2DOUBLE | false | 0ALL | null | This study will test the safety and effectiveness of a range of doses of MK0476 (montelukast) compared to placebo on improved lung function in patients with chronic asthma. | null | Chronic Asthma | Chronic asthma | null | 4 | arm 1: montelukast Placebo arm 2: montelukast arm 3: montelukast arm 4: montelukast | [
2,
0,
0,
0
] | 2 | [
0,
0
] | intervention 1: 5 Period, Cross-over, Dose-Ranging study. Period I: no treatment. Periods II-V: Single-dose administration of inhaled montelukast (using doses as low as 25 mcg, to as high as 1000 mcg), or montelukast placebo. Two puffs of albuterol or albuterol placebo will be given four hours after montelukast/montelu... | intervention 1: Comparator: montelukast intervention 2: Comparator: placebo | 0 | null | 0 | NCT00739297 |
[
3
] | 1 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | The purpose of this study is to determine how safe and effective Abatacept is in treating patients who have progressive pulmonary sarcoidosis. | null | Sarcoidosis | null | 1 | arm 1: None | [
5
] | 1 | [
0
] | intervention 1: 10mg/kg IV (infusion directly into the vein of the arm) Day 1, week 2, week 4 and then every 4 week for 44 weeks. | intervention 1: Abatacept | 1 | Chicago | Illinois | United States | -87.65005 | 41.85003 | 0 | NCT00739960 | |
[
4
] | 9 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | The purpose of this study is to determine the efficacy and safety of donepezil hydrochloride (Aricept) in the treatment of cognitive dysfunction shown by children with Down syndrome, aged 6 to 10 years. | This is a multinational study with sites in the US, India, Singapore, South Korea, Mexico and Chile. There will be 210 subjects (male or female) enrolled that are residing in community or facilities with a reliable caregiver that have been clinically diagnosed with Down syndrome. The assessments performed during this s... | Down Syndrome Cognitive Dysfunction | pediatric Down syndrome cognitive dysfunction Downs Aricept children with Down syndrome | null | 2 | arm 1: None arm 2: None | [
1,
2
] | 2 | [
0,
0
] | intervention 1: All subjects will start with a dose of 1.25 mg/day (1.25 ml) donepezil ; dose escalations will occur every 2 weeks to a maximum of 5 mg/day (5 ml) donepezil.
All doses will be administered orally. intervention 2: All subjects will start with a dose of 1.25 mg/day (1.25 ml) placebo; dose escalations wil... | intervention 1: Aricept (Donepezil hydrochloride) intervention 2: Placebo | 2 | San Antonio | Texas | United States | -98.49363 | 29.42412
Herndon | Virginia | United States | -77.3861 | 38.96955 | 0 | NCT00754013 |
[
4
] | 8 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | The purpose of this study is to determine the efficacy and safety of donepezil hydrochloride (Aricept) in the treatment of the cognitive dysfunction shown by children with Down syndrome, aged 11 to 17. | The study will be conducted in approximately 75 sites in the US, India, Singapore, South Korea, Mexico and Chile and will include 210 participants to be enrolled. | Down Syndrome Cognitive Dysfunction | Pediatric Down syndrome Downs Cognitive Dysfunction of Down syndrome | null | 3 | arm 1: None arm 2: None arm 3: None | [
1,
1,
2
] | 3 | [
0,
0,
0
] | intervention 1: All participants will start with a dose of 2.5 mg/day (2.5 ml) donepezil ; dose escalation will occur every 2 weeks to a maximum of 5 mg/day (5 ml) donepezil. All doses will be administered orally. intervention 2: All participants will start with a dose of 2.5 mg/day (2.5 ml) donepezil ; dose escalation... | intervention 1: Aricept (donepezil hydrochloride) intervention 2: Aricept (donepezil hydrochloride) intervention 3: Placebo | 2 | San Antonio | Texas | United States | -98.49363 | 29.42412
Herndon | Virginia | United States | -77.3861 | 38.96955 | 0 | NCT00754052 |
[
3
] | 30 | RANDOMIZED | PARALLEL | 0TREATMENT | 3TRIPLE | false | 0ALL | false | The purpose of this study is to evaluate the safety and efficacy of AN2728 Ointment, 5%, compared to Ointment Vehicle, applied twice daily for 12 weeks, in the treatment of plaque type psoriasis | This is a single center, randomized, double-blind, vehicle-controlled, bilateral design. Patients will apply both test articles, AN2728 Ointment, 5%, and Ointment Vehicle twice daily for 12 weeks. The assigned study medication will be applied to two comparable treatment targeted plaques identified at baseline. One test... | Psoriasis | Plaque Type Psoriasis Topical | null | 2 | arm 1: AN2728 Ointment, 5% arm 2: AN2728 Ointment vehicle | [
1,
2
] | 2 | [
0,
0
] | intervention 1: AN2728 Ointment, 5%, twice daily for 12 weeks intervention 2: Ointment vehicle, twice daily for 12 weeks | intervention 1: AN2728 intervention 2: Ointment vehicle | 1 | Mexico City | Mexico City | Mexico | -99.12766 | 19.42847 | 0 | NCT00755196 |
[
2
] | 25 | RANDOMIZED | CROSSOVER | 0TREATMENT | 2DOUBLE | false | 0ALL | false | This study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of MK1006 | null | Type 2 Diabetes Mellitus | null | 12 | arm 1: Participants received 15 mg MK1006 in Period 1, followed by placebo to MK1006 in Period 2, followed by 45 mg MK1006 in Period 3, followed by 60 mg MK1006 in Period 4, followed by placebo to MK1006 taken with food (Fed state) in Period 5. arm 2: Participants received placebo to MK1006 in Period 1, followed by 30 ... | [
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0
] | 2 | [
0,
0
] | intervention 1: MK1006 capsules: 1 mg, 10 mg, and 20 mg.
Panel A: MK1006 capsules in five doses beginning at 15 mg and rising to 60 mg
Panel B: MK1006 capsules in five doses beginning at 60 mg and rising to 140 mg.
Panel C: MK1006 capsules in five doses beginning at 140 mg and rising to 260 mg.
There will a 7-day i... | intervention 1: MK1006 intervention 2: Placebo | 0 | null | 0 | NCT00757601 | |
[
5
] | 500 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | null | The purpose of this study is to collect disease burden of OA and the effectiveness and patient satisfaction of treatment by Etoricoxib in the normal practice setting. | null | Pain | null | 1 | arm 1: Etoricoxib | [
0
] | 1 | [
0
] | intervention 1: etoricoxib 60 mg QD for 4 weeks. | intervention 1: etoricoxib | 0 | null | 0 | NCT00757627 | |
[
4
] | 60 | RANDOMIZED | PARALLEL | 0TREATMENT | 1SINGLE | true | 0ALL | true | Clinical research study to determine the effectiveness of a triclosan/copolymer/fluoride toothpaste in maintaining periodontal health and therefore glycaemic control in a type 2 diabetic population. | null | Periodontitis | null | 2 | arm 1: Brush whole mouth 2x/day for 12 months with triclosan/copolymer/fluoride toothpaste. arm 2: Swish whole mouth 2x/day for 12 months with fluoride mouthrinse. | [
1,
2
] | 2 | [
0,
0
] | intervention 1: Brush whole mouth 2x/day for 12 months with triclosan/copolymer/fluoride toothpaste. Return for required clinical visits @ 12 months for scaling, root planing and donation samples of dental plaque and blood for microbiological analyses. intervention 2: Swished around whole mouth twice daily for 12 month... | intervention 1: Triclosan/copolymer/fluoride intervention 2: Fluoride | 0 | null | 0 | NCT00762762 | |
[
4
] | 626 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | true | 0ALL | false | Hypersensitivity | null | Dentin Hypersensitivity | null | 2 | arm 1: sensitive toothpaste arm 2: Triclosan control toothpaste | [
0,
1
] | 2 | [
0,
0
] | intervention 1: Brush twice daily intervention 2: Brush twice daily | intervention 1: Triclosan, Silicon dioxide, fluoride intervention 2: Triclosan, fluoride | 1 | Cedar Knolls | New Jersey | United States | -74.44876 | 40.82204 | 0 | NCT00763269 | |
[
3
] | 45 | RANDOMIZED | FACTORIAL | null | 0NONE | true | 0ALL | false | To date, no study has investigated whether there is a drug interaction between the protease inhibitor fosamprenavir and the entry inhibitor maraviroc. COL112237 is a randomized, open-label, 6-arm, 3-period, drug interaction study to assess steady-state plasma amprenavir (APV) and maraviroc (MVC) pharmacokinetics in 48 ... | This randomized, open-label, six-arm, three-period drug interaction study will recruit 48 healthy volunteers so as to obtain a minimum of 36 evaluable subjects at a single study center in the U.S. The study will have a screening visit, 3 treatment visits for PK sampling and a follow-up visit. The screening visit will b... | Healthy | Healthy Subjects Pharmacokinetics study Pharmacokinetics of medications | null | 6 | arm 1: Period 1-Maraviroc 300mg BID Period 2- Fosamprenavir 1400mg BID Period 3- Fosamprenavir 1400mg BID + Maraviroc 300mg BID arm 2: Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 1400mg BID + Maraviroc 300mg BID Period 3-Fosamprenavir 1400mg BID arm 3: Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 700mg B... | [
1,
1,
1,
1,
1,
1
] | 3 | [
0,
0,
0
] | intervention 1: 300 mg BID intervention 2: 1400 mg BID, 700 mg BID or 1400 mg QD intervention 3: 100 mg BID, 100 mg QD | intervention 1: Maraviroc intervention 2: Fosamprenavir intervention 3: Ritonavir | 1 | Voorhees Township | New Jersey | United States | -74.49062 | 40.4795 | 0 | NCT00764465 |
[
3
] | 5 | NA | SINGLE_GROUP | 0TREATMENT | 2DOUBLE | false | 0ALL | true | • To determine the safety and efficacy of Botox Treatment in subjects with mild to moderate acne vulgaris defined by the Investigator's Global Assessment (IGA) | • 90 day trial, with botox being injected at baseline/screening visit. Photos will be taken throughout the study and patients will be evaluated by masked injector evaluator and a masked evaluator. Patient will complete a subject evaluation at each visit. Follow-up visits occur at Day 3, 7, 14, 30 and 90. | Acne Vulgaris | acne Botox cosmetic treatments | null | 1 | arm 1: Botulinum Neurotoxin Type A (Botox, 1.5-3 units/lesion); Bacteriostatic saline solution (0.11 cc/lesion) | [
0
] | 2 | [
0,
0
] | intervention 1: 1.5-3 units of Botox/lesion intervention 2: .1 cc bacteriostatic saline/lesion | intervention 1: Botulinum Neurotoxin Type A intervention 2: Bacteriostatic saline | 1 | Chicago | Illinois | United States | -87.65005 | 41.85003 | 0 | NCT00765375 |
[
2
] | 34 | RANDOMIZED | PARALLEL | 1PREVENTION | 0NONE | false | 0ALL | false | This is a 36 week dietary intervention pilot study to evaluate the effects of lyophilized black raspberries on rectal polyp burden and biomarkers in subjects with FAP. Subjects will undergo a colonoscopy or sigmoidoscopy before study treatment to determine eligibility for the study. Eligible participants will undergo a... | null | Familial Adenomatous Polyposis | Polyp, Familial Adenomatous Polyposis, Prevention | null | 2 | arm 1: 20 grams BRB Slurry BID plus two, 730 mg BRB suppositories HS arm 2: 20 grams BRB Placebo Slurry BID plus two, 730 mg BRB suppositories HS | [
0,
0
] | 3 | [
0,
0,
0
] | intervention 1: 20 grams BRB Slurry intervention 2: Two, 730 mg BRB suppositories QHS intervention 3: 20 grams BRB placebo slurry | intervention 1: Black raspberry (BRB) Slurry intervention 2: Black Raspberry (BRB) Suppositories intervention 3: Black Raspberry (BRB) Placebo Slurry | 1 | Cleveland | Ohio | United States | -81.69541 | 41.4995 | 0 | NCT00770991 |
[
5
] | 165 | RANDOMIZED | CROSSOVER | 0TREATMENT | 4QUADRUPLE | false | 0ALL | null | This study will evaluate the efficacy and safety of Dex-Methylphenidate Extended Release 30 mg compared to 20 mg in pediatric patients ages 6-12 with Attention-Deficit Hyperactivity Disorder (ADHD) in a 12-hour laboratory classroom setting. | null | Attention-Deficit/Hyperactivity Disorder (ADHD) | ADHD, children, subjects, laboratory classroom | null | 3 | arm 1: Dex-Methylphenidate hydrochloride (Focalin® XR) 30 mg dose (one 20 mg capsule and one 10 mg capsule) orally once a day for 7 days. arm 2: Dex-Methylphenidate hydrochloride (Focalin® XR) one 20 mg capsule orally once a day for 7 days. arm 3: Two Capsules taken orally once a day for 7 days | [
0,
1,
2
] | 2 | [
0,
0
] | intervention 1: 10 mg and/or 20 mg capsules intervention 2: Placebo Comparator | intervention 1: Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) intervention 2: Placebo | 8 | Little Rock | Arkansas | United States | -92.28959 | 34.74648
Bradenton | Florida | United States | -82.57482 | 27.49893
South Miami | Florida | United States | -80.29338 | 25.7076
Overland Park | Kansas | United States | -94.67079 | 38.98223
Las Vegas | Nevada | United States | -115.13722 | 36.17497
Houston | Texas | ... | 0 | NCT00776009 |
[
0
] | 26 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | The purpose of this study is to determine the response rate of the combination of bortezomib and melphalan in patients with Acute Myelogenous Leukemia (AML) or high-risk Myelodysplastic Syndromes (MDS). | In patients who develop acute myelogenous leukemia (AML) or a high-risk myelodysplastic syndrome (MDS), the current standard treatment involves multidrug induction chemotherapy utilizing an anthracycline or anthraquinone with cytarabine. While chemotherapy has proven effective at inducing remission in up to 90% of pati... | Acute Myelogenous Leukemia Myelodysplastic Syndromes | Acute Myelogenous Leukemia AML Myelodysplastic Syndromes MDS Melphalan Bortezomib Velcade | null | 1 | arm 1: All patients will receive the following regimen: 1) Melphalan 2 mg orally, once daily. 2) Bortezomib 1.0 mg/M2 IV on days 1, 4, 8, 11. | [
0
] | 3 | [
0,
0,
0
] | intervention 1: Melphalan: 2mg orally, once daily intervention 2: Bortezomib: 1.0mg/M2 IV on days 1, 4, 8, 11 intervention 3: None | intervention 1: Melphalan intervention 2: Bortezomib intervention 3: Melphalan and bortezomib | 2 | Jacksonville | Florida | United States | -81.65565 | 30.33218
Lebanon | New Hampshire | United States | -72.25176 | 43.64229 | 0 | NCT00789256 |
[
3
] | 132 | RANDOMIZED | PARALLEL | 7BASIC_SCIENCE | 2DOUBLE | false | 0ALL | false | The purpose of the study is to assess the safety of the study drug, Patanase (Olopatadine Hydrochloride Nasal Spray 0.6%) compared to placebo (inactive substance) in children ages 2 to less than 6 who have a history of nasal allergies, and to assess the pharmcokinetics (study of the action of a drug in the body) in the... | null | Allergic Rhinitis | Allergic Rhinitis Pediatric PATANASE | null | 2 | arm 1: Olopatadine Hydrochloride Nasal Spray 0.6% arm 2: Olopatadine Hydrochloride Nasal Spray Vehicle | [
0,
2
] | 2 | [
0,
0
] | intervention 1: one spray in each nostril twice daily for 2 weeks intervention 2: one spray in each nostril twice daily for 2 weeks | intervention 1: Olopatadine Hydrochloride Nasal Spray 0.6% intervention 2: Olopatadine Hydrochloride Nasal Spray Vehicle | 1 | Waco | Texas | United States | -97.14667 | 31.54933 | 0 | NCT00794144 |
[
4
] | 2 | NON_RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | null | The purpose of this study is to evaluate the effectiveness and safety of Osmotic Release Oral System (OROS) hydromorohone Hydrochloride (HCl) compared with morphine sustain release (SR) in participants with chronic (lasting a long time) malignant (cancerous) cancer pain. | This is an open-label (all people know the identity of the intervention), multi-center (when more than 1 hospital or medical school team work on a medical research study), active-controlled, randomized (the study drug is assigned by chance) study to evaluate safety and efficacy of OROS extended-release (ER) hydromorhon... | Cancer Pain | Pain Hydromorphone hydrochloride OROS Morphine | null | 2 | arm 1: Participants will receive hydromorphone HCl OROS 8 milligram (mg) every 24 hours, for 3 to 14 days of titration phase. Hydromorphone HCl OROS will be continued as per Investigator's discretion for next 14 days of maintenance phase. arm 2: Participants will receive morphine SR 8 mg every 24 hours, for 3 to14 days... | [
0,
1
] | 2 | [
0,
0
] | intervention 1: Participants will receive hydromorphone HCl OROS 8 milligram (mg) every 24 hours, for 3 to 14 days of titration phase. Hydromorphone HCl OROS will be continued as per Investigator's discretion for next 14 days of maintenance phase. intervention 2: Participants will receive morphine SR 8 mg every24 hours... | intervention 1: Hydromprphone Hydrochloride (HCl) OROS intervention 2: Morphine Sustain Release (SR) | 0 | null | 0 | NCT00803283 |
[
5
] | 30 | RANDOMIZED | CROSSOVER | 0TREATMENT | 4QUADRUPLE | false | 0ALL | false | This study compares patient symptoms and anterior segment safety in patients treated with timolol hemihydrate, generic timolol gel forming solution or timolol maleate. | null | Glaucoma, Open Angle Ocular Hypertension | null | 6 | arm 1: Period one - Timolol hemihydrate 0.5% Period two - Timolol maleate 0.5% Period three - Timolol maleate gel forming solution 0.5% arm 2: Period one - Timolol maleate 0.5% Period two - Timolol maleate gel forming solution 0.5% Period three - Timolol hemihydrate 0.5% arm 3: Period one - Timolol maleate gel forming ... | [
1,
1,
1,
1,
1,
1
] | 3 | [
0,
0,
0
] | intervention 1: 0.5% intervention 2: 0.5% intervention 3: 0.5% | intervention 1: Timolol Maleate in Sorbate intervention 2: Timolol hemihydrate intervention 3: Timolol maleate gel forming solution | 2 | Bourbonnais | Illinois | United States | -87.88754 | 41.15376
Charlotte | North Carolina | United States | -80.84313 | 35.22709 | 0 | NCT00804648 | |
[
5
] | 30 | RANDOMIZED | CROSSOVER | null | 1SINGLE | true | 0ALL | false | The purpose of this study is to compare Prilosec OTC® and Zegerid® in their effects on gastric acid suppression. | null | Normal Healthy Subject Population | null | 2 | arm 1: Zegerid® arm 2: Prilosec OTC® | [
1,
0
] | 2 | [
0,
0
] | intervention 1: capsule(20 mg omeprazole/sodium bicarbonate), single dose intervention 2: Omeprazole-magnesium 20.6 mg, tablet, single dose | intervention 1: Zegerid® intervention 2: Prilosec OTC® | 1 | Oklahoma City | Oklahoma | United States | -97.51643 | 35.46756 | 0 | NCT00808769 | |
[
5
] | 226 | RANDOMIZED | PARALLEL | 1PREVENTION | 4QUADRUPLE | true | 1FEMALE | false | This study proposes a double blind randomized clinical trial to include normal weight and obese women who have normal ovulatory function at baseline; the investigators will randomize women to 2 widely used OCs and evaluate ovarian follicle development and circulating progesterone to assess ovarian suppression during OC... | There is a large gap between lowest expected failure rates of about 1.5% and typical use failure rates of about 7% per year. This gap may be due to incorrect use or to decreased oral contraceptive (OC) effectiveness in population subgroups. Recent reports suggest greater OC failure among heavier women, particularly tho... | Ovarian Suppression | Ovarian Suppression Oral Contraceptives Obese and Normal BMI | null | 2 | arm 1: Participants with a BMI of 19-24.9 kg/m\^2 arm 2: Participants with a BMI of 30-39.9 kg/m\^2 | [
1,
1
] | 2 | [
0,
0
] | intervention 1: Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use.
Dose formula contains 20 ug of ethinyl estradiol (EE) and 100 ug of levonor... | intervention 1: Low dose formulation intervention 2: High dose formulation | 1 | New York | New York | United States | -74.00597 | 40.71427 | 0 | NCT00827632 |
[
2
] | 52 | RANDOMIZED | CROSSOVER | 7BASIC_SCIENCE | 0NONE | true | 2MALE | false | The major aim of this study is to investigate and compare the drug amount delivered to the body after sequential application of 2 rotigotine transdermal patches from 2 different manufacturing processes. | null | Healthy | Rotigotine Neupro® Transdermal Patch | null | 2 | arm 1: Two single applications of rotigotine patches from two different manufacturing processes in the order A-B separated by a washout phase of at least 5 days arm 2: Two single applications of rotigotine patches from two different manufacturing processes in the order B-A separated by a washout phase of at least 5 day... | [
0,
0
] | 1 | [
0
] | intervention 1: Rotigotine 4.5mg/10cm\^2 patch applied for 24 hours | intervention 1: Rotigotine transdermal patch | 1 | Neuss | North Rhine-Westphalia | Germany | 6.68504 | 51.19807 | 0 | NCT00881894 |
[
3
] | 5 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | Evaluation of CD4 in combination with CHO chemotherapy in subjects with nodal involvement of non cutaneous Tcell lymphoma. | null | T-cell Lymphoma | non cutaneous peripheral t-cell lymphoma with nodal involvement | null | 2 | arm 1: CHOP chemo therapy + CD4 therapy arm 2: CHOP chemotherapy | [
0,
1
] | 2 | [
2,
0
] | intervention 1: None intervention 2: None | intervention 1: CHOP + CD4 intervention 2: CHOP | 0 | null | 0 | NCT00893516 |
[
4
] | 85 | NON_RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | This study will provide data on additional therapeutic benefits in administering Adalimumab in patients with plaque psoriasis that showed an unsatisfactory response after at least 3 months of treatment with etanercept. | A total of 50 patients with psoriasis vulgaris who showed an unsatisfactory response to etanercept 50 mg twice a week followed by 50 mg once a week and a total of 50 patients who showed an unsatisfactory response to etanercept 50 mg twice a week without dose reduction will be recruited. All patients will receive adalim... | Plaque Psoriasis | Adalimumab | null | 4 | arm 1: Patients who have shown an unsatisfactory response to 3 months of etanercept 50 mg twice a week without dose reduction prior to screening. arm 2: Patients who showed a satisfactory response to 3 months or more of etanercept 50 mg twice a week followed by a loss of response after dose reduction to 50 mg etanercep... | [
0,
0,
0,
0
] | 2 | [
0,
0
] | intervention 1: Adalimumab 40mg injection every other week for 24 weeks intervention 2: Adalimumab 40mg injection every week for the last 12 weeks of study. | intervention 1: Adalimumab every other week intervention 2: Adalimumab Every Week | 12 | Winnipeg | Manitoba | Canada | -97.14704 | 49.8844
St. John's | Newfoundland and Labrador | Canada | -52.70931 | 47.56494
London | Ontario | Canada | -81.23304 | 42.98339
London | Ontario | Canada | -81.23304 | 42.98339
Markham | Ontario | Canada | -79.2663 | 43.86682
Oakville | Ontario | Canada | -79.68292 | 43.45011
... | 0 | NCT00927069 |
[
5
] | 24 | RANDOMIZED | CROSSOVER | 7BASIC_SCIENCE | 0NONE | true | 2MALE | false | The purpose of this protocol is to study if two different tablet formulations of doxycycline are bioequivalent to each other. | null | Bacterial Infection | Bioequivalence | null | 2 | arm 1: None arm 2: None | [
0,
1
] | 2 | [
0,
0
] | intervention 1: Tablet, 100 mg, Single dose intervention 2: Tablet, 100 mg, Single dose | intervention 1: doxycycline monohydrate tablet intervention 2: doxycycline carragenate tablet | 1 | Ahmedabad | Gujarat | India | 72.58727 | 23.02579 | 0 | NCT00939562 |
[
5
] | 1 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | Study Status:
Duke University Health System Institutional Review Board has received notification of study termination; final IRB closure date is 12/12/2008. Study enrollment is now closed.
Enrollment Update:
Only one subject was entered into this study out of an expected enrollment of 15 patients in this single site... | This is an open-label study using alefacept in the treatment of patients with chronic plaque psoriasis who have not responded to treatment with an anti-TNF agent. Patients not responding to Enbrel® 50 mg weekly with a 75% reduction of Psoriasis Area and Severity Index (PASI) Score or a Physician Global Assessment (PGA)... | Chronic Plaque Psoriasis | null | 1 | arm 1: Alefacept will be given to subjects with plaque psoriasis who have failed treatment with Fnbrel. | [
0
] | 1 | [
0
] | intervention 1: Alefacept 15 mg IM once a week were to be administered for 12 weeks, which is the FDA approved dosage, duration, and frequency. This study allowed an additional 8 doses if subject did not achieve a 'clear' response with the original 12 weeks of treatment. Each enrolled subject must have failed a respons... | intervention 1: alefacept | 0 | null | 0 | NCT00953329 | |
[
2
] | 26 | RANDOMIZED | PARALLEL | 1PREVENTION | 3TRIPLE | true | 2MALE | false | The purpose of this study is to determine whether testosterone (male hormone) therapy is effective if administered in a cyclic fashion (periodic dosing) compared to continuous dosing in men aged 60 to 85 years. Effectiveness will be determined based on improvements in body composition, muscle metabolism, muscle strengt... | Men and women undergo a progressive reduction in lean muscle mass (sarcopenia) with advancing age regardless of their level of physical activity. A 12-yr longitudinal study in healthy sedentary older men showed a correlation between loss of muscle cross-sectional area and muscle strength of the thigh, quadriceps, and f... | Hypogonadism | Low Normal Testosterone Male Aging | null | 3 | arm 1: Weekly placebo treatment for a duration of 5 months. arm 2: A month of weekly testosterone treatment alternated by a month of weekly placebo treatment for a duration of 5 months. arm 3: Weekly testosterone treatment for a duration of 5 months | [
2,
0,
0
] | 2 | [
0,
0
] | intervention 1: Weekly im injections of 100 mg testosterone enanthate. intervention 2: Weekly IM injections of sesame oil. | intervention 1: Testosterone intervention 2: Placebo | 1 | Galveston | Texas | United States | -94.7977 | 29.30135 | 0 | NCT00957528 |
[
0
] | 16 | RANDOMIZED | CROSSOVER | 0TREATMENT | 0NONE | false | 0ALL | false | The investigators hypothesize that the use of an oral dose of Terbutaline or a 20% basal reduction will be able to prevent nocturnal hypoglycemia after an afternoon exercise session. This is a randomized three period cross-over study including treatment with Terbutaline, a 20% basal reduction for six hours, or no treat... | In this study, a minimum of 16 youth with type 1 diabetes will be recruited. All subjects must have been diagnosed with type 1 diabetes for at least one year and on an insulin pump for at least one month. Subjects are between the ages of 10 and 17 years, inclusive, have an HbA1c less than 10.0% and normal thyroid funct... | Type 1 Diabetes | Children Exercise Hypoglycemia | null | 3 | arm 1: Subjects complete the same exercise routine, however no treatment is given at 9:00pm. arm 2: Subjects complete same exercise routine. At 9:00pm, an oral dose of 2.5 mg of Terbutaline is administered. arm 3: All subjects complete the same exercise session. At 9:00pm, subject's basal rate is decreased by 20% for s... | [
1,
0,
0
] | 3 | [
0,
10,
10
] | intervention 1: Oral (2.5mg) one time administration at 9:00pm intervention 2: Basal insulin rate is reduced by 20% the normal (home dose) for six hours. intervention 3: No treatment is given for the study. This arm is for comparison with the two intervention arms. | intervention 1: Terbutaline intervention 2: 20% basal insulin reduction intervention 3: Control | 1 | Aurora | Colorado | United States | -104.83192 | 39.72943 | 0 | NCT00974051 |
[
4
] | 41 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | The primary objective is to evaluate the efficacy (as measured by the rate of recurrent symptomatic Venous Thromboembolism \[VTE\] (i.e., Pulmonary thromboembolism \[PE\] and Deep Vein Thrombosis \[DVT\])) and safety of GSK576428 as the initial treatment in subjects with acute PE in an open-label design. | null | Embolism, Pulmonary | Fondaparinux sodium contrast-enhanced MDCT Deep Vein Thrombosis Pulmonary thromboembolism | null | 2 | arm 1: None arm 2: None | [
0,
5
] | 2 | [
0,
0
] | intervention 1: The dose of Fondaparinux will be determined based on a subject's body weight (\<50 kg, 5 mg; 50 to 100 kg, 7.5 mg; \>100 kg, 10 mg) and administered once daily by subcutaneous (SC) injection. intervention 2: UFH therapy will be started on Day 1 while adjusting activated partial thromboplastin time (aPTT... | intervention 1: Fondaparinux sodium intervention 2: unfractionated heparin (UFH) | 27 | Aichi | N/A | Japan | 130.62158 | 32.51879
Chiba | N/A | Japan | 140.11667 | 35.6
Fukuoka | N/A | Japan | 130.41667 | 33.6
Gunma | N/A | Japan | N/A | N/A
Gunma | N/A | Japan | N/A | N/A
Hokkaido | N/A | Japan | N/A | N/A
Hokkaido | N/A | Japan | N/A | N/A
Hyōgo | N/A | Japan | 144.43333 | 43.36667
Ibaraki | N/A | Japa... | 0 | NCT00981409 |
[
4
] | 54 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 2MALE | false | The purpose of this study is to investigate whether 6 months treatment with the cholesterol-lowering drug rosuvastatin may reduce visceral fat tissue in obese middle aged men. | The accumulation of intra-abdominal fat has been suggested to be of primary importance in the development of the metabolic syndrome and associated metabolic disturbances and it has been hypothesized that a selective reduction of visceral fat tissue would improve the symptoms of the metabolic syndrome. Treatment with st... | Abdominal Obesity | null | 2 | arm 1: None arm 2: None | [
1,
2
] | 2 | [
0,
0
] | intervention 1: 10 mg once daily intervention 2: once daily | intervention 1: Rosuvastatin intervention 2: Placebo for rosuvastatin | 1 | Gothenburg | N/A | Sweden | 11.96679 | 57.70716 | 0 | NCT01068626 | |
[
3
] | 40 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 1FEMALE | false | The primary objective of this study was to demonstrate the superiority of SKY0402 over conventional, commercially-available bupivacaine HCl with respect to the duration of the analgesic effect achieved by a single local administration of the study drug. | This was a Phase 2, parallel-group, active-control, randomized, double-blind study conducted to evaluate a single local administration of low dose or high dose of SKY0402 compared with 75 mg of bupivacaine HCl (i.e., Marcaine® 0.5%) in women undergoing bilateral, cosmetic, sub-muscular, augmentation mammoplasty under g... | Postoperative Pain | Breast augmentation Pain Analgesia | null | 2 | arm 1: Marcaine with epinephrine 1:200,000 is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402 arm 2: Marcaine with epinephrine 1:200,000 is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402 | [
1,
1
] | 2 | [
0,
0
] | intervention 1: Low-dose SKY0402 administered locally into one breast pocket and 75 mg bupivacaine HCl administered locally into the other breast pocket intervention 2: Mid-dose SKY0402 administered locally into one breast pocket and 75 mg bupivacaine HCl administered locally into the other breast pocket | intervention 1: SKY0402 + bupivacaine HCl intervention 2: Mid-dose SKY0402 + bupivacaine HCl | 1 | La Jolla | California | United States | -117.2742 | 32.84727 | 0 | NCT01206608 |
[
3
] | 30 | RANDOMIZED | CROSSOVER | 0TREATMENT | 1SINGLE | false | 0ALL | null | The purpose of this study is to assess the pharmacokinetics, efficacy and safety of T2345 versus an active comparator. | null | Primary Open Angle Glaucoma | null | 2 | arm 1: One drop. arm 2: One drop | [
1,
0
] | 2 | [
0,
0
] | intervention 1: One drop at 8.00pm. intervention 2: One drop at 8.00pm. | intervention 1: T2345 intervention 2: Prostaglandin | 0 | null | 0 | NCT01494753 | |
[
4
] | 188 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | The purpose of this study is to explore the tolerability, safety and efficacy of flexibly dosed paliperidone extended release (ER) among patients with schizophrenia. | This is a single arm (the same intervention is given to all patients), multicenter study that aimed to explore the tolerability, safety and efficacy of flexibly dosed paliperidone extended release (ER) among Filipino patients with schizophrenia who have not taken any antipsychotics in the past, and among newly diagnose... | Schizophrenia | Schizophrenia Paliperidone ER Treatment naive patients Newly diagnosed patients | null | 1 | arm 1: None | [
0
] | 1 | [
0
] | intervention 1: Type= range, unit= mg/day, number= 3 to 12, form= tablet, route= oral use. Paliperidone ER 6 mg orally administered once daily for the first five days. Thereafter, flexible dosing in a range of 3 to 12 mg/day. | intervention 1: Paliperidone ER | 0 | null | 0 | NCT01606228 |
[
0
] | 140 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | This is a randomized controlled trial comparing extracorporeal shockwave lithotripsy (ESWL) with and without simultaneous adjunct controlled inversion therapy in the treatment of lower pole caliceal stone. | null | Kidney Stone | null | 2 | arm 1: ESWL with hydration and inversion arm 2: ESWL with hydration | [
0,
1
] | 3 | [
3,
3,
0
] | intervention 1: Patients inverted 30 degree head down in Trendelenburg position intervention 2: Shock wave lithotripsy intervention 3: Hydration of patient with 0.5L NaCl and 20mg frusemide IV | intervention 1: Inversion intervention 2: Shock Wave Lithotripsy intervention 3: Hydration | 0 | null | 0 | NCT01852669 | |
[
4
] | 160 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 1FEMALE | false | The purpose of this comparative study is to evaluate the efficacy of an ovule with triple active agents (terconazole, clindamycin and fluocinolone) versus another ovule with triple active agents (nystatin, metronidazole and fluocinolone) in the treatment of symptoms caused by the presence of vaginitis (inflammation of ... | This is a prospective (study following participants forward in time), open-label (all people know the identity of the intervention), randomized (the study drug is assigned by chance), comparative, parallel (a clinical trial comparing the response in 2 or more groups of participants receiving different treatments) doubl... | Vaginitis Infectious Vaginosis | Vaginitis Infectious vaginosis Terconazole Clindamycin Fluocinolone Metronidazole Nystatin | null | 2 | arm 1: One ovule containing 80 milligram (mg) terconazole, 100 mg clindamycin and 0.5 mg fluocinolone acetonide will be administered vaginally, every 24 hours at night, for 3 days. arm 2: One ovule containing 500 mg metronidazole, 0.5 mg fluocinolone acetonide and 100,000.00 microgram/milliliter nystatin will be admini... | [
0,
0
] | 2 | [
0,
0
] | intervention 1: One ovule containing 80 milligram (mg) terconazole, 100 mg clindamycin and 0.5 mg fluocinolone acetonide will be administered vaginally, every 24 hours at night, for 3 days. intervention 2: One ovule containing 500 mg metronidazole, 0.5 mg fluocinolone acetonide and 100,000.00 microgram/milliliter nysta... | intervention 1: Gynoclin V intervention 2: Vagitrol V | 2 | DF | Mexico City | Mexico | N/A | N/A
Mexico City | N/A | Mexico | -99.12766 | 19.42847 | 0 | NCT01867164 |
[
3
] | 6 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | This study assessed the pharmacodynamic effects of patiromer on serum potassium in participants on hemodialysis. | The initial intent was to enroll 12-24 adult male and female participants on hemodialysis into the study. Due to significant recruitment challenges, the study was discontinued after six participants were enrolled in the study.
This was an open-label, multiple-dose, adaptive-design study in participants on hemodialysis... | Hyperkalemia | null | 1 | arm 1: None | [
0
] | 1 | [
0
] | intervention 1: 15 grams/day (5 grams 3 times daily) administered orally | intervention 1: patiromer | 2 | Orlando | Florida | United States | -81.37924 | 28.53834
Minneapolis | Minnesota | United States | -93.26384 | 44.97997 | 0 | NCT02033317 | |
[
4
] | 16 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | null | This study will compare the efficacy of CellCept \[0.5-2 grams per day (g/day) orally (p.o.)\] and cyclophosphamide \[0.5-1 grams per square meter (g/m2) quarterly\] as maintenance treatment for patients with lupus nephritis. All patients will receive induction treatment with cyclophosphamide (0.5-1g/m2 monthly) for 6 ... | null | Lupus Nephritis | null | 2 | arm 1: Induction Phase (Months 1 through 6): Participants received cyclophosphamide, 0.5 to (-) 1 grams per square meter (g/m\^2), intravenously (IV) pulse once per month. Participants also received prednisone, 1 milligram per kilogram per day (mg/kg/day), orally (PO); the dose was reduced by 5 mg/day to a final dose o... | [
0,
1
] | 4 | [
0,
0,
0,
0
] | intervention 1: 1 g/day, PO BID for 2 weeks; 1.5 g/day PO TID for the next 2 weeks; and 2 g/day PO BID for the remainder of the Maintenance Phase. intervention 2: 0.5-1 g/m\^2 IV pulse once every 3 months intervention 3: 0.5 - 1 g/m\^2 IV pulse once per month intervention 4: 1 mg/kg PO once per day; reduced by 5 mg eve... | intervention 1: Mycophenolate mofetil (MMF) intervention 2: Cyclophosphamide, Maintenance Phase intervention 3: Cyclophosphamide, Induction Phase intervention 4: Prednisone | 2 | Barquisimeto | N/A | Venezuela | -69.35703 | 10.0647
Caracas | N/A | Venezuela | -66.87919 | 10.48801 | 0 | NCT02081183 | |
[
2
] | 16 | RANDOMIZED | CROSSOVER | 0TREATMENT | 2DOUBLE | true | 2MALE | false | To investigate the effect of three single oral doses of BIA 9-1067 (25 mg, 50 mg and 100 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of immediate-release levodopa/carbidopa 100/25 mg (Sinemet® 100/25) | Single centre, double-blind, randomized, placebo-controlled, crossover study with four consecutive single-dose treatment periods. The washout period between doses was to be at least 14 days. On each treatment period, after completion of pre-dose assessments, BIA 9-1067/Placebo was to be administered concomitantly with ... | Parkinson's Disease (PD) | Parkinson's disease (PD) Opicapone BIA 9-1067 | null | 4 | arm 1: Period 1: BIA 9-1067 25 mg Period 2: BIA 9-1067 50 mg Period 3: BIA 9-1067 100 mg Period 4: Placebo
BIA 9- 067/Placebo was to be administered concomitantly with the a single-dose of immediate-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® 100/25 arm 2: Period 1: BIA 9-1067 50 mg Period 2: BIA 9-1067... | [
0,
0,
0,
0
] | 3 | [
0,
0,
0
] | intervention 1: OPC, Opicapone intervention 2: PLC, Placebo intervention 3: Immediate-release levodopa/carbidopa 100/25 mg | intervention 1: BIA 9-1067 intervention 2: Placebo intervention 3: Sinemet® 100/25 | 1 | Mount Royal | Quebec | Canada | -73.64918 | 45.51675 | 0 | NCT02169479 |
[
2
] | 17 | NON_RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | null | This study will assess the safety and tolerability, and make a preliminary assessment of activity, of a combination of pertuzumab and erlotinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have failed on at least one prior chemotherapy regimen. The anticipated time on study tre... | null | Non-Small Cell Lung Cancer | Non-Squamous | null | 2 | arm 1: Participants will receive IV infusion of pertuzumab at a loading dose of 840 mg on Day 1, followed by a dose of 420 mg every 3 weeks. Erlotinib will be administered daily, at a dose level of 100 mg orally (PO). arm 2: Participants will receive IV infusion of pertuzumab at a loading dose of 840 mg on Day 1, follo... | [
0,
0
] | 2 | [
0,
0
] | intervention 1: Erlotinib will be administered as oral tablets. intervention 2: Pertuzumab will be administered as intravenous (IV) infusion. | intervention 1: Erlotinib intervention 2: Pertuzumab | 3 | Antwerp | N/A | Belgium | 4.40026 | 51.22047
Barcelona | N/A | Spain | 2.15899 | 41.38879
Manchester | N/A | United Kingdom | -2.23743 | 53.48095 | 0 | NCT02507375 |
[
4
] | 31 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | null | This study evaluated the efficacy and safety of 48-week treatment with pegylated interferon (PEG-IFN) alfa-2a (Pegasys) monotherapy in participants with chronic hepatitis D (CHD). Treatment was followed by 24 weeks of treatment-free follow-up. | null | Hepatitis D, Chronic | null | 1 | arm 1: Participants received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 48 weeks, followed by 24 weeks of treatment-free follow-up. | [
0
] | 1 | [
0
] | intervention 1: Participants received pegylated interferon (PEG-IFN) alfa-2a 180 microgram (mcg) subcutaneously (SC) weekly for 48 weeks. | intervention 1: Pegylated Interferon (PEG-IFN) alfa-2a | 7 | Bucharest | N/A | Romania | 26.10626 | 44.43225
Bucharest | N/A | Romania | 26.10626 | 44.43225
Cluj-Napoca | N/A | Romania | 23.6 | 46.76667
Constanța | N/A | Romania | 28.63432 | 44.18073
Craiova | N/A | Romania | 23.8 | 44.31667
Iași | N/A | Romania | 27.6 | 47.16667
Timișoara | N/A | Romania | 21.22571 | 45.75372 | 0 | NCT02732639 | |
[
2
] | 48 | RANDOMIZED | SEQUENTIAL | 0TREATMENT | 2DOUBLE | true | 0ALL | false | The primary objective of this study was to assess the safety, tolerability, and immunogenicity potential of romosozumab following multiple subcutaneous (SC) administrations in healthy men and postmenopausal women with low bone mass. | null | Postmenopausal Osteopenia | null | 2 | arm 1: Participants were randomized to receive matching placebo administered by subcutaneous injection once every 2 weeks (Q2W) or once every 4 weeks (Q4W) for 3 months. arm 2: Participants were randomized to receive romosozumab administered by subcutaneous injection at doses of 1 mg/kg Q2W, 2 mg/kg Q4W, 2 mg/kg Q2W, o... | [
2,
0
] | 2 | [
0,
0
] | intervention 1: Administered by subcutaneous injection intervention 2: Administered by subcutaneous injection | intervention 1: Romosozumab intervention 2: Placebo | 0 | null | 0 | NCT01825785 | |
[
3
] | 54 | RANDOMIZED | PARALLEL | 0TREATMENT | 3TRIPLE | false | 0ALL | false | Trial to determine the maximum tolerated dose (MTD) based on safety and tolerability of MK-8777 (Org 26576, SCH 900777) in participants with major depressive disorder. | This is a randomized, placebo-controlled, safety and tolerability study examining MK-8777 in participants with major depressive disorder. In Part I of the trial, four different cohorts of six participants each will receive multiple rising doses of MK-8777 (ranging from 100 mg twice a day \[BID\] to 300 mg BID) or place... | Depression | randomized placebo controlled maximum tolerated dose | null | 11 | arm 1: Participants receive MK-8777 initiated at 100 mg BID and titrated to a maximum of 600 mg BID. Participants receive MK-8777 for a total of 16 days. arm 2: Participants receive placebo BID for a total of 16 days. arm 3: Participants receive MK-8777 initiated at 200 mg BID and titrated to a maximum of 600 mg BID. P... | [
0,
2,
0,
2,
0,
2,
0,
2,
0,
0,
2
] | 2 | [
0,
0
] | intervention 1: Orally administered capsules containing either 50 mg or 100 mg MK-8777. intervention 2: Orally administered matching placebo capsules. | intervention 1: MK-8777 intervention 2: Placebo | 0 | null | 0 | NCT00610649 |
[
3
] | 5 | RANDOMIZED | PARALLEL | 0TREATMENT | 1SINGLE | false | 0ALL | false | This is a single-blind, placebo-controlled, parallel group study to evaluate the efficacy of BRL29060A (paroxetine hydrochloride hydrate, hereafter paroxetine) administered orally over the dose range of 20 mg to 50 mg once daily after supper for 12 weeks in Japanese patients with posttraumatic stress disorder (PTSD) as... | null | Post-Traumatic Stress Disorder Stress Disorders, Post-Traumatic | PTSD (Posttraumatic Stress Disorder) CAPS fMRI Paroxetine | null | 2 | arm 1: Drug 2 (20 mg/day or placebo) will be administered once daily after supper for the first two weeks after the run-in phase. If the investigator/subinvestigator judges that a sufficient response is achieved, Drug 2 will be continued for the remaining period. If a sufficient response is not achieved with Drug 2 but... | [
0,
2
] | 2 | [
0,
10
] | intervention 1: BRL29060A (paroxetine hydrochloride hydrate, hereafter paroxetine) administered orally over the dose range of 20 mg to 50 mg once daily after supper for 12 weeks in Japanese patients with posttraumatic stress disorder (PTSD) intervention 2: placebo | intervention 1: paroxetine intervention 2: placebo | 9 | Chiba | N/A | Japan | 140.11667 | 35.6
Chiba | N/A | Japan | 140.11667 | 35.6
Tokyo | N/A | Japan | 139.69171 | 35.6895
Tokyo | N/A | Japan | 139.69171 | 35.6895
Tokyo | N/A | Japan | 139.69171 | 35.6895
Tokyo | N/A | Japan | 139.69171 | 35.6895
Tokyo | N/A | Japan | 139.69171 | 35.6895
Tokyo | N/A | Japan | 139.69171 ... | 0 | NCT00557622 |
[
2
] | 17 | RANDOMIZED | CROSSOVER | 0TREATMENT | 2DOUBLE | false | 0ALL | false | The purpose of this study is to evaluate the effect of SCH 497079 on metabolic parameters and to determine the influence of race/ethnic origin on therapeutic response. | This study includes two parts, each part includes three consecutive 28-day treatment periods. Part 1 (to be conducted in the United States): each participant will receive the following treatments for 28 days in each of three treatment periods in an order determined by a random code: SCH 497079, or matching placebo, or ... | Type 2 Diabetes Mellitus | null | 6 | arm 1: Participants received SCH 497079 daily for 4 weeks followed by placebo daily for 4 weeks followed by metformin daily for 4 weeks. arm 2: Participants received placebo daily for 4 weeks followed by metformin daily for 4 weeks followed by SCH 497079 daily for 4 weeks. arm 3: Participants received metformin daily f... | [
0,
0,
0,
0,
0,
0
] | 3 | [
0,
0,
0
] | intervention 1: SCH 497079 100 mg capsule, administered orally, once daily for 4 weeks intervention 2: Placebo capsules matching SCH 497079, administered orally, once daily for 4 weeks intervention 3: Metformin extended release 750 mg, 2 tablets administered orally, once daily for 4 weeks (1500 mg total daily dose) | intervention 1: SCH 497079 intervention 2: Placebo intervention 3: Metformin | 0 | null | 0 | NCT00673465 | |
[
3
] | 117 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | null | The purpose of this study is to determine the safety of donepezil hydrochloride (Aricept) in children with Down syndrome who have finished the preceding 10-week, double-blind study of donepezil hydrochloride. Medical tests for drug safety will be conducted at each clinic visit. | All children in this study will take donepezil hydrochloride once a day, and will come back to the clinic at 8, 24 and 42 weeks after the study has begun. In between these clinic visits, the clinical staff will telephone the child's parent or caregiver to discuss drug safety observations and possible changes in drug do... | Down Syndrome | null | 1 | arm 1: All participants started with a dose of 2.5 mg/day (2.5 mL/day). Dose escalations occurred in 2.5 mg/day increments every 2 weeks (steady state levels assumed to have been reached) to a maximum dose of 10 mg/day, according to the participant's weight schedule and the Investigator's judgment of safety and tolerab... | [
0
] | 1 | [
0
] | intervention 1: Liquid form Aricept - 5 mg/5 mL donepezil hydrochloride. | intervention 1: Donepezil hydrochloride (Aricept) | 31 | Phoenix | Arizona | United States | -112.07404 | 33.44838
Little Rock | Arkansas | United States | -92.28959 | 34.74648
Los Angeles | California | United States | -118.24368 | 34.05223
Oakland | California | United States | -122.2708 | 37.80437
Orange | California | United States | -117.85311 | 33.78779
San Diego | Cal... | 0 | NCT00675025 | |
[
3
] | 10 | RANDOMIZED | CROSSOVER | 0TREATMENT | 2DOUBLE | false | 0ALL | null | The purpose of this research study is to look at concentrations of GSK189075 in blood when single doses of the drug are taken by mouth in combination with basal insulin. The clinical effects of the drug in combination with insulin on the body will also be studied. The results will help determine doses of GSK189075 can ... | null | Diabetes Mellitus, Type 1 | type 1 Diabetes mellitus, pharmacokinetics, pharmacodynamics Adult male and females, | null | 2 | arm 1: GSK189075 arm 2: Placebo | [
0,
2
] | 2 | [
0,
0
] | intervention 1: investigational drug intervention 2: placebo comparator | intervention 1: GSK189075 intervention 2: placebo | 1 | San Diego | California | United States | -117.16472 | 32.71571 | 0 | NCT00575159 |
[
4
] | 142 | RANDOMIZED | CROSSOVER | 0TREATMENT | 3TRIPLE | false | 0ALL | false | To evaluate the efficacy of LDX compared to placebo in adults with ADHD in the adult workplace environment (AWE) setting | This study has both an optimization and double-blind period | ADHD | null | 2 | arm 1: None arm 2: None | [
1,
2
] | 2 | [
0,
0
] | intervention 1: oral, 30, 50, or 70 mg once-daily for 4 weeks during dose optimization, and then for 1 week during each crossover during the adult workplace environment setting intervention 2: Placebo administered once-daily for one week during the adult workplace environment setting | intervention 1: LDX intervention 2: Placebo | 5 | Little Rock | Arkansas | United States | -92.28959 | 34.74648
Irvine | California | United States | -117.82311 | 33.66946
Overland Park | Kansas | United States | -94.67079 | 38.98223
Las Vegas | Nevada | United States | -115.13722 | 36.17497
Houston | Texas | United States | -95.36327 | 29.76328 | 0 | NCT00697515 | |
[
4
] | 301 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 1FEMALE | null | The objective of the study was to assess the long-term safety of daily doses of ospemifene 60 mg in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women without a uterus. | null | Atrophy Vaginal Diseases | Menopausal symptoms Vulvar and vaginal atrophy in menopausal women Vaginal atrophy Urogenital atrophy | null | 1 | arm 1: Participants will take one tablet of ospemifene 60 mg orally, once a day for 12 weeks. | [
0
] | 1 | [
0
] | intervention 1: None | intervention 1: Ospemifene 60Mg Oral Tablet | 0 | null | 1 | NCT01586364 |
[
3
] | 576 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | The purpose of this study is to evaluate the efficacy and safety of GSK233705B compared with placebo in subjects with COPD. | null | Pulmonary Disease, Chronic Obstructive | COPD Multicenter GSK233705B double-blind Chronic Obstructive Pulmonary Disease (COPD) randomized | null | 6 | arm 1: GSK233705 12.5mcg arm 2: GSK233705 25mcg arm 3: GSK233705 50mcg arm 4: GSK233705 100mcg arm 5: GSK233705 200mcg arm 6: Placebo | [
0,
0,
0,
0,
0,
2
] | 6 | [
0,
0,
0,
0,
0,
0
] | intervention 1: Once daily via dry powder inhaler intervention 2: once daily via dry powder inhaler intervention 3: Once daily via dry powder inhaler intervention 4: Once daily via dry powder inhaler intervention 5: Once daily via dry powder inhaler intervention 6: Once daily via dry powder imhaler | intervention 1: GSK233705 12.5mcg intervention 2: GSK233705 25mcg intervention 3: GSK233705 50mcg intervention 4: GSK233705 100mcg intervention 5: GSK233705 200mcg intervention 6: Placebo | 88 | Jasper | Alabama | United States | -87.27751 | 33.83122
Glendale | Arizona | United States | -112.18599 | 33.53865
Fountain Valley | California | United States | -117.95367 | 33.70918
Fullerton | California | United States | -117.92534 | 33.87029
Los Angeles | California | United States | -118.24368 | 34.05223
Los Ange... | 0 | NCT00676052 |
[
3
] | 27 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 1FEMALE | false | The purpose of this study is to determine whether the CollaRx Bupivacaine Implant is safe and effective in reducing the amount of narcotic pain medication needed to control pain during the first 96 hours after abdominal hysterectomy when compared to the ON-Q PainBuster Post-op Pain Relief System. | Hysterectomy is the second most common surgery among women in the United States (US). Abdominal hysterectomy surgery may be performed to treat benign tumors, such as fibroids, heavy periods, painful periods and chronic pelvic pain. The most common route for performing hysterectomy is through an incision in the abdomina... | Pain, Postoperative | Abdominal Hysterectomy Postoperative pain | null | 2 | arm 1: Three Bupivacaine sponges placed at different levels within the surgical cavity; one deep within the vault, one at the incision line in the peritoneum and one at the dermal incision line. arm 2: Insertion of the ON-Q system catheter into the deep subcutaneous space overlying the fascia. | [
0,
1
] | 2 | [
0,
0
] | intervention 1: The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride intervention 2: 5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL \[900 mg\]) | intervention 1: Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant) intervention 2: ON-Q PainBuster Post-op Pain relief System | 1 | Boynton Beach | Florida | United States | -80.06643 | 26.52535 | 0 | NCT00749749 |
[
3
] | 564 | RANDOMIZED | PARALLEL | 0TREATMENT | 3TRIPLE | false | 1FEMALE | true | This is a 12 month study designed to evaluate the safety and effectiveness of SB-751689 in the treatment of osteoporosis in post-menopausal women, in comparison with 2 active comparators and placebo. | null | Osteoporosis | bone mineral density, Ronacaleret teriparatide alendronate, Post-menopausal women, osteoporosis, SB-751689 | null | 4 | arm 1: All subjects will take calcium (500-660mg elemental daily) and vitamin D (at least 400IU daily) supplements once daily in the evening throughout the study arm 2: All subjects will take calcium (500-660mg elemental daily) and vitamin D (at least 400IU daily) supplements once daily in the evening throughout the st... | [
4,
1,
1,
0
] | 3 | [
0,
0,
0
] | intervention 1: 100mg, 200mg, 300mg, 400mg intervention 2: PTH (1-34) intervention 3: Bisphosphonate | intervention 1: Ronacaleret intervention 2: Teriparatide intervention 3: Alendronate | 49 | Oakland | California | United States | -122.2708 | 37.80437
Palm Desert | California | United States | -116.37697 | 33.72255
Walnut Creek | California | United States | -122.06496 | 37.90631
Decatur | Georgia | United States | -84.29631 | 33.77483
Bethesda | Maryland | United States | -77.10026 | 38.98067
Akron | Ohio ... | 0 | NCT00471237 |
[
3
] | 69 | RANDOMIZED | PARALLEL | 4SUPPORTIVE_CARE | 4QUADRUPLE | false | 0ALL | true | To investigate the effects of rhIGF-I/rhIGFBP-3 treatment for 24 weeks on endurance, ambulation, cognitive functioning, insulin resistance, lipid levels, muscle function and strength, pain, gastrointestinal functioning, and quality of life endpoints in DM1 patients | Efficacy Measures:
Endurance, Ambulation, Cognitive function, Insulin resistance, Cholesterol and triglycerides, Muscle function and strength, Pain, Gastrointestinal function, Quality of life
MINIMUM INCLUSION CRITERIA
1. A diagnosis of DM1, confirmed by DM1 genetic mutation
2. Age 21 to 65 years (inclusive)
3. Abil... | Myotonic Dystrophy Type 1 | null | 2 | arm 1: None arm 2: None | [
0,
2
] | 2 | [
0,
0
] | intervention 1: 1.0 mg/kg rhIGF-I/rhIGFBP-3 or placebo daily, subcutaneous injections from baseline through the last day of the end of study visit. intervention 2: 1.0 mg/kg rhIGF-I/rhIGFBP-3 or placebo daily, subcutaneous injections from baseline through the last day of the end of study visit. | intervention 1: rhIGF-I/rhIGFBP-3 intervention 2: placebo | 12 | Orange | California | United States | -117.85311 | 33.78779
Sacramento | California | United States | -121.4944 | 38.58157
Kansas City | Kansas | United States | -94.62746 | 39.11417
Baltimore | Maryland | United States | -76.61219 | 39.29038
Minneapolis | Minnesota | United States | -93.26384 | 44.97997
St Louis | Mis... | 0 | NCT00577577 | |
[
3
] | 76 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | This is a continuation of a pilot study which is now regarded as a phase II trial with a plan to enroll an additional 40 patients (20 related and 20 unrelated donor transplants) with hematological malignancy assessing the safety and efficacy of a minimally myelosuppressive regimen with pentostatin and low-dose total bo... | This is a pilot study which began with a plan to enroll 50 patients (20 related and 30 unrelated donor transplants) with hematological malignancy assessing the safety and efficacy of a minimally myelosuppressive regimen with Pentostatin and low-dose total body irradiation (TBI) followed by allogeneic peripheral blood s... | Acute Myelogenous Leukemia Acute Lymphocytic Leukemia Chronic Myelogenous Leukemia Chronic Lymphocytic Leukemia Myelodysplastic Syndromes Multiple Myeloma Non-Hodgkins Lymphoma Hodgkins Disease Peripheral T-cell Lymphoma | null | 1 | arm 1: Pentostatin to be administered intravenously on days - 10, -9, and -8 at a dose of 4mg/m2/day | [
0
] | 5 | [
0,
4,
0,
0,
0
] | intervention 1: 4 mg/m\^2 intravenous(IV)once a day(QD)x3days (days -10, -9, -8) intervention 2: TBI will consist of 2.0 GY at 8-12cGy/min via 6MV photons delivered AP/PA fields, without lung blocks or via lateral fields with lucite compensator along the head and neck region. TLD (thermal luminescent dosimetry) will be... | intervention 1: Pentostatin intervention 2: Total-body irradiation (TBI) intervention 3: Cyclosporine A (CsA) intervention 4: Mycophenolate Mofetil (MMF) intervention 5: G-CSF | 1 | Omaha | Nebraska | United States | -95.94043 | 41.25626 | 0 | NCT00571662 | |
[
3
] | 8 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | Dexmedetomidine is a sedative drug approved for adult patients, intubated, in intensive care units. We are studying whether this drug is cardiovascularly safe in pediatric patients who have recently been burned. | This is an ascending dose study evaluating the cardiovascular safety of dexmedetomidine bolus/infusions in acutely burned pediatric patients. The study entails a bolus of dexmedetomidine, followed by 2 hours of increasing infusion doses. Cardiovascular parameters including EKG, heart rate, oxygen saturation, blood pres... | Burns Sedation | pediatric burn sedation | null | 1 | arm 1: Ascending doses of dexmedetomidine (as per protocol) | [
0
] | 1 | [
0
] | intervention 1: Dexmedetomidine bolus 1 ug/kg over 10 minutes, followed by ascending infusion as follows: Dexmedetomidine \[in ug/kg/hr\], each for 15 minutes: 0.7, 1.0, 1.3, 1.6, 1.9, 2.2, 2.5. | intervention 1: Dexmedetomidine | 1 | Boston | Massachusetts | United States | -71.05977 | 42.35843 | 0 | NCT00697788 |
[
5
] | 199 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | null | This study attempts to differentiate the clinical responses of Choline Acetyltransferase and Apolipoprotein Epsilon gene polymorphism to donepezil in Alzheimer's Disease patients. | null | Alzheimer's Disease | Alzheimer's disease | null | 1 | arm 1: None | [
0
] | 1 | [
0
] | intervention 1: 2.5mg once daily for the first 7 days, 5mg once daily for the next 3 weeks, after then the dose can be increased 10mg once daily under the investigator's decision. | intervention 1: Donepezil | 15 | Bundang | N/A | South Korea | N/A | N/A
Changwon | N/A | South Korea | 128.68111 | 35.22806
Chuncheon | N/A | South Korea | 127.73417 | 37.87472
Chungju | N/A | South Korea | 127.9287 | 36.97666
Daegu | N/A | South Korea | 128.59111 | 35.87028
Daejeon | N/A | South Korea | 127.38493 | 36.34913
Gyeonggi-do | N/A | South... | 0 | NCT00381381 |
[
4
] | 602 | RANDOMIZED | PARALLEL | 1PREVENTION | 0NONE | false | 1FEMALE | false | This protocol is designed to compare the effect on bone of Zoledronic Acid 4 mg every 6 months when given upfront versus delayed start (based on a post-baseline BMD T- Score below -2.0 SD at either the lumbar spine or total hip, or any clinical fracture unrelated to trauma, or an asymptomatic fracture discovered at the... | null | Breast Neoplasms Osteoporosis | cancer-treatment related bone loss postmenopausal women breast cancer hormone receptor positive breast cancer adjuvant therapy hormonal therapy bone loss bisphosphonates ZFAST Letrozole Zoledronic Acid US32 | null | 2 | arm 1: Participants in the upfront arm received zoledronate 4 mg i.v. on Day 1 and every 6 months until disease progression (recurrence) or the end of study. Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily. arm 2: In lieu of a placebo arm, which was considered... | [
0,
0
] | 2 | [
0,
0
] | intervention 1: Participants received Zoledronate 4 mg IV 15-minute infusion every 6 months. intervention 2: Participants received Letrozole 2.5 mg daily. | intervention 1: Zoledronic Acid intervention 2: Letrozole | 44 | Springdale | Arkansas | United States | -94.12881 | 36.18674
Burbank | California | United States | -118.30897 | 34.18084
Lafayette | California | United States | -122.11802 | 37.88576
LaVerne | California | United States | N/A | N/A
Long Beach | California | United States | -118.18923 | 33.76696
Montebello | Californi... | 1 | NCT00050011 |
[
4
] | 577 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | null | The purpose of the study is to evaluate the effectiveness and safety of olmesartan versus placebo on the progression of diabetic renal disease. | null | Diabetic Nephropathy Type 2 Diabetes Mellitus Proteinuria | angiotensin II type I receptor blockers diabetic nephropathy end-stage renal disease renal failure type 2 diabetes olmesartan medoxomil | null | 2 | arm 1: Olmesartan medoxomil tablets 10mg to 40 mg arm 2: Matching placebo tablets | [
0,
2
] | 2 | [
0,
0
] | intervention 1: Tablets 10, 20, or 40 mg intervention 2: Matching placebo tablets | intervention 1: olmesartan medoxomil intervention 2: Placebo Tablets | 2 | Hong Kong | N/A | China | 114.17469 | 22.27832
Tokyo | N/A | Japan | 139.69171 | 35.6895 | 1 | NCT00141453 |
[
3
] | 172 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | The purpose of this study is to learn whether HKI-272 is safe and effective in treating non-small cell lung cancer. | null | Carcinoma, Non-Small-Cell Lung Lung Neoplasms | Lung Cancer HKI-272 Neratinib Nerlynx | null | 3 | arm 1: HKI-272 administered to patients whose disease has progressed following \> or = 12 weeks of treatment with Tarceva or Iressa and who have a tumor with an EGFR mutation demonstrated at screening arm 2: HKI-272 administered to patients whose disease has progressed following \> or = 12 weeks of treatment with Tarce... | [
0,
0,
0
] | 1 | [
0
] | intervention 1: 320mg or 240mg daily by mouth. The starting dose was reduced from 320mg to 240mg per amendment #1 to the protocol for subject safety and tolerability. | intervention 1: HKI-272 | 19 | Los Angeles | California | United States | -118.24368 | 34.05223
Zion | Illinois | United States | -87.83285 | 42.44613
Boston | Massachusetts | United States | -71.05977 | 42.35843
Minneapolis | Minnesota | United States | -93.26384 | 44.97997
New York | New York | United States | -74.00597 | 40.71427
Charlotte | Nort... | 1 | NCT00266877 |
[
5
] | 355 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | true | The purpose of this study is to compare the effectiveness of two antipsychotic medications, Risperdal® Consta® versus Abilify®, over a 2-year treatment period in the long-term maintenance of patients with schizophrenia. | Although many patients with schizophrenia currently take oral antipsychotic medications, it is estimated that up to 75% of them have difficulty adhering to the daily oral regimen. Long-acting injectable formulations of antipsychotics may eliminate the need for daily medication and enhance patient compliance with the tr... | Schizophrenia Psychotic Disorders | Schizophrenia Relapse Remission Treatment Outcome long-acting injectable | null | 2 | arm 1: None arm 2: None | [
1,
0
] | 2 | [
0,
0
] | intervention 1: 10-30 mg once daily for 104 weeks intervention 2: 25mg, 37.5mg, or 50mg every 2 weeks for 104 weeks | intervention 1: Abilify intervention 2: Risperidal Consta | 0 | null | 1 | NCT00299702 |
[
4
] | 3,221 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | true | The purpose of this study is to learn whether apixaban prevents the development of blood clots in the leg (deep vein thrombosis) and lung (pulmonary embolism), which sometimes occur after knee replacement surgery, and to compare the efficacy of apixaban with that of enoxaparin (Lovenox®) in the prevention of these clot... | null | Deep Vein Thrombosis Pulmonary Embolism | Prevention of deep vein thrombosis and pulmonary embolism after total knee replacement surgery | null | 2 | arm 1: Participants received apixaban, 2.5-mg tablets twice daily (BID), plus a matching enoxaparin-placebo injection 12 (±3) hours prior to hip-replacement surgery through 11 (±2) days after the day of surgery. arm 2: Participants received enoxaparin, 40-mg subcutaneous injection once daily (QD), plus a matching apixa... | [
0,
1
] | 4 | [
0,
0,
0,
0
] | intervention 1: 40 mg, administered once daily by subcutaneous injection, for 12 days intervention 2: 2.5 mg, administered twice daily as tablets, for 12 days intervention 3: Administered once daily by subcutaneous injection intervention 4: Oral tablet administered twice daily | intervention 1: Enoxaparin intervention 2: Apixaban intervention 3: Enoxaparin-matching placebo intervention 4: Apixaban-matching placebo | 122 | Graz | N/A | Austria | 15.45 | 47.06667
Innsbruck | N/A | Austria | 11.39454 | 47.26266
Linz | N/A | Austria | 14.28611 | 48.30639
Vienna | N/A | Austria | 16.37208 | 48.20849
Vienna | N/A | Austria | 16.37208 | 48.20849
Wels | N/A | Austria | 14.03333 | 48.16667
Wiener Neustadt | N/A | Austria | 16.23196 | 47.80485
An... | 1 | NCT00452530 |
[
4
] | 903 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | true | The purpose of this study is to compare the efficacy and safety of CNTO 1275 to etanercept in patients with moderate to severe plaque psoriasis. | This is a multicenter, randomized (study medication assigned by chance), active-controlled, parallel, 3-arm study. Patients will be randomly (allocation to treatments available by chance) assigned in 3:5:5 ratio to receive one of three treatments groups. The three treatment groups are: Group 1 - CNTO 1275 45 mg dosing ... | Psoriasis | Psoriasis CNTO 1275 Etanercept Immune diorder Skin disorder | null | 3 | arm 1: Patients will receive CNTO 1275 45 mg at the Weeks 0 and 4 visits. Treatment after Week 12 is dependent on Physician's Global Assessment (PGA) response at Week 12 and initial treatment assignment. arm 2: Patients will receive CNTO 1275 90 mg at the Weeks 0 and 4 visits. Treatment after Week 12 is dependent on PG... | [
0,
0,
1
] | 3 | [
0,
0,
0
] | intervention 1: Type=exact number, number=45, unit=mg, form=injection, route=subcutaneous intervention 2: Type=exact number, number=90, unit=mg, form=injection, route=subcutaneous intervention 3: Type=exact number, number=50, unit=mg, form=injection, route=subcutaneous | intervention 1: CNTO 1275 45 mg intervention 2: CNTO 1275 90 mg intervention 3: Etanercept 50 mg | 0 | null | 0 | NCT00454584 |
[
4
] | 452 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | The purpose of this study is to compare the efficacy of paliperidone palmitate and risperidone long acting injection (LAI) in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) alon... | This is a randomized (assigned by chance), open-label (all people know the identity of the intervention), active-controlled, parallel-group (a medical research study comparing the response in two or more groups of participants receiving different treatments), multicenter (when more than one hospital or medical school t... | Schizophrenia | Schizophrenia Paliperidone Paliperidone palmitate Risperidone Risperidone long acting injection R092670 | null | 2 | arm 1: Paliperidone palmitate suspension for intramuscular injection at a dose of 150 milligram equivalent (mg eq.) at baseline, 100 mg eq. on Day 8, flexible dose, either 50 or 100 mg eq on Day 36 and 50, 100, or 150 mg eq.on Day 64 depending on investigator's discretion. arm 2: Risperidone LAI intramuscular at a dose... | [
0,
1
] | 2 | [
0,
0
] | intervention 1: Paliperidone palmitate suspension for intramuscular injection at a dose of 150 milligram equivalent (mg eq.) at baseline, 100 mg eq. on Day 8, flexible dose, either 50 or 100 mg eq on Day 36 and 50, 100, or 150 mg eq.on Day 64 depending on investigator's discretion. intervention 2: Risperidone LAI intra... | intervention 1: Paliperidone palmitate (R092670) intervention 2: Risperidone | 8 | Baoding | N/A | China | 115.46246 | 38.87288
Beijing | N/A | China | 116.39723 | 39.9075
Guangzhou | N/A | China | 113.25 | 23.11667
Hangzhou | N/A | China | 120.16142 | 30.29365
Nanjing | N/A | China | 118.77778 | 32.06167
Shanghai | N/A | China | 121.45806 | 31.22222
Wuhan | N/A | China | 114.26667 | 30.58333
Xi'an |... | 1 | NCT00604279 |
[
3
] | 22 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 2MALE | false | This is a clinical trial of orally administered Ruxolitinib (INCB018424) in patients whose disease has progressed following 1 prior chemotherapy regimen (not including anti-androgens or ketoconazole) for metastatic, androgen-independent prostate cancer. | null | Prostate Cancer | Prostate Cancer | null | 1 | arm 1: Participants received ruxolitinib 25 mg orally twice daily in 12-hour intervals for 21-day cycles for as long as the study medication was tolerated and provided clinical benefit. | [
0
] | 1 | [
0
] | intervention 1: Ruxolitinib 25 mg tablets taken with water twice a day. | intervention 1: Ruxolitinib | 15 | Highland | California | United States | -117.20865 | 34.12834
Montebello | California | United States | -118.10535 | 34.00946
Mountain View | California | United States | -122.08385 | 37.38605
Galesburg | Illinois | United States | -90.37124 | 40.94782
Overland Park | Kansas | United States | -94.67079 | 38.98223
Wichi... | 1 | NCT00638378 |
[
4
] | 305 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | The primary objectives of this study are to evaluate the safety \& efficacy of consecutive treatments of Clobex® Spray and Silkis® Ointment in the management of plaque psoriasis. | Same as above. | Psoriasis | null | 1 | arm 1: clobetasol propionate spray 0.05%
Other Names:
Clobex® Spray 0.05% clobetasol propionate spray, 0.05%, applied topically twice daily
calcitriol ointment
Other Names:
Calcitriol Ointment calcitriol ointment, 3 µg/g, applied topically, not to exceed 30 g daily | [
1
] | 2 | [
0,
0
] | intervention 1: clobetasol propionate spray, 0.05%, applied topically twice daily intervention 2: calcitriol ointment, 3 µg/g, applied topically, not to exceed 30 g daily | intervention 1: clobetasol propionate spray 0.05% intervention 2: calcitriol ointment | 12 | San Diego | California | United States | -117.16472 | 32.71571
Newnan | Georgia | United States | -84.79966 | 33.38067
Snellville | Georgia | United States | -84.01991 | 33.85733
Evansville | Indiana | United States | -87.55585 | 37.97476
New York | New York | United States | -74.00597 | 40.71427
Warren | Ohio | United... | 1 | NCT00658788 | |
[
4
] | 588 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | The purpose of this study is to compare the pain relieving effect of different doses of MK0663 with placebo and other pain relievers/analgesics in patients with postoperative dental pain. Pain intensity and relief will be measured by the total pain relief score (TOPAR) and patient evaluation. | null | Postoperative Dental Pain | Postoperative Dental Pain | null | 5 | arm 1: etoricoxib 90 mg arm 2: etoricoxib 120 mg arm 3: ibuprofen 2400 mg arm 4: acetaminophen 2400 mg/codeine 240 mg arm 5: Matching Placebo | [
0,
0,
1,
1,
2
] | 4 | [
0,
0,
0,
0
] | intervention 1: etoricoxib 90 mg; 120 mg (once daily) over three days. intervention 2: ibuprofen 2400 mg (600 mg Q6h) over three Days intervention 3: acetaminophen 2400 mg/codeine 240 mg (600/60 mg Q6h) over three Days intervention 4: matching placebo over three Days | intervention 1: Comparator: etoricoxib intervention 2: Comparator: ibuprofen intervention 3: Comparator: acetaminophen + codeine intervention 4: Comparator: placebo | 0 | null | 1 | NCT00694369 |
[
4
] | 237 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | The purpose of the study is to learn if long-term treatment with DVS SR is safe for treating the pain and other symptoms associated with diabetic peripheral neuropathy. | null | Diabetic Neuropathy, Painful | Diabetic Peripheral Neuropathy | null | 1 | arm 1: Daily dose of 100mg or 200mg at the investigators discretion. Subjects already randomized at a dose of 400mg may continue at that dose level. | [
5
] | 1 | [
0
] | intervention 1: None | intervention 1: Desvenlafaxine Succinate Sustained-Release (DVS SR) | 0 | null | 1 | NCT01050218 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.